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Cardiovascular diseases, such as ischaemic heart disease, remain the most common cause of 
death worldwide. With no effective treatment to replace the loss of cardiac tissue following a 
myocardial infarction, ischaemic heart disease places a significant socioeconomic burden on 
medicine. Advances in medical research have introduced new potential treatments, of which 
regenerative medicine such as stem cell therapy seem to be promising for cardiac repair. 
Various stem cell types have been investigated, which have different effects in cardiac repair. 
Combination of different cell types have been shown to improve the therapeutic potential 
which is thought to be due to synergistic or complimentary reparative effects. 
Recently, cardiac progenitor cells (CPC) isolated from the right atrial appendage (RAA) and 
left ventricle have been shown to have different functional effects in vitro. Importantly, 
conditioned media (CM) from CPCs from the right atrial appendage (RAA CPC) have 
superior cardioprotective effects, while CM from the left ventricle (LV CPC) have superior 
angiogenic effects. Due to these distinct functional paracrine effects, this study investigated if 
the combination of RAA CPCs and LV CPCs from the same patient exert synergistic or 
complimentary paracrine effects for cardioprotection and angiogenesis in an in vitro model. 
Both RAA CPCs and LV CPCs expressed the mesenchymal cell markers CD90 and CD105, 
and were predominantly negative for the haematopoietic cell marker, CD34. CPCs were 
cultured either alone or in combination and exposed to serum deprivation and hypoxic 
conditions (1% O2) to stimulate ischaemia. Normoxic conditions (20% O2) was used as a 
control. Gene expression of HIF1A, AKT1, FGF2 and PDGFA were measured to investigate 
the cellular responses to stimulated ischaemia. HIF1A mRNA expression was significantly 
decreased in the combination group of RAA CPCs and LV CPCs (RAA + LV) cultured in 
 iii 
hypoxia and in hypoxia irrespective of groups. There were no significant differences in the 
expression of AKT1, FGF2 and PDGFA. 
To measure the paracrine effects of CPCs, CM was collected following stimulated ischaemia. 
IGF-1 (pro-survival factor) and VEGF-A (pro-angiogenic factor) concentrations in CM were 
measured. IGF-1 concentration was comparable across all CPC groups. However, VEGF-A 
concentration was increased in CM collected from hypoxia, especially in the RAA and RAA 
+ LV hypoxic CM. CM from all CPC groups reduced apoptosis in AC16 cardiomyocyte cell 
line exposed to stimulated ischaemia. Interestingly, RAA + LV normoxic CM was the only 
group that significantly increased the expression of HIF-1α protein in AC16 cardiomyocytes 
exposed to stimulated ischaemia. CM from all CPC groups induced angiogenesis in human 
umbilical vein endothelial cells and was the highest in the RAA + LV hypoxic CM. 
Overall, this study provides evidence that combination of RAA CPCs and LV CPCs may have 
greater therapeutic effects and have synergistic paracrine effects for cardiac repair. Therefore, 
in vivo studies are warranted to determine if combination of different stem cell types have 
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Cardiovascular disease (CVD) is the leading cause of mortality globally with an estimated 
17.9 million deaths annually. Ischaemic heart disease (IHD), a condition characterised by 
decreased blood supply to the heart, is the predominant cause of death in CVD accounting for 
8.9 million deaths, approximately half (49.7%) of CVD deaths.(1) In IHD, the reduced blood 
supply to the heart results in ischaemic stress to the myocardium. This eventually leads to 
myocardial infarction (MI) resulting in reduced cardiac function, as well as death and loss of 
cardiac cells. In some cases, MI leads to subsequent adverse cardiac remodelling which can 
progress towards heart failure (HF), an end stage heart disease. Improvements in 
cardiovascular management has led to a steady decrease in mortality rates and an increase in 
median age of cardiovascular deaths in patients with CVD in developed countries, which 
consequently increases the proportion of deaths caused by HF.(2) 
Current available treatment can delay progression towards heart failure but is unable to 
replace the lost cardiovascular cells, which is essential for long-term improvement of cardiac 
function in patients with IHD and HF. While orthotopic heart transplantation is the only 
option to achieve this, limited availability of donor hearts makes transplantation a clinically 
not feasible option.(3) 
Stem cell therapy holds great promise for their potential to repair and regenerate cardiac tissue 
lost in IHD and HF. Currently different stem cell populations are being investigated to 
identify the best cell source for therapy. Of various stem cell types, cardiac stem cells (CSC) 
were shown to have better effects on cardiac repair compared to other adult stem cell (ASC) 
populations and seem to be a promising candidate for cardiac repair.(4) Furthermore, a 
combination of different stem cell types which have synergistic or complimentary effects may 
produce greater therapeutic effects than single cell therapies.(5) Improvements in cardiac 
function following stem cell therapy are attributable to several mechanisms including 
differentiation of stem cells into cells of the cardiovascular lineage such as cardiomyocytes, 
endothelial cells and smooth muscle cells, and paracrine mediated effects.(6,7) 
A recent study shows that different populations of stem cells in the heart have different 
functional qualities, with cardiac progenitor cells (CPC) from the right atrial appendage (RAA 
CPC) have better cell survival potential and CPCs from the left ventricle (LV CPC) have 
better angiogenic potential, which are major targets for cardiac repair.(8) 
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1.1 Ischaemic heart disease 
1.1.1 Pathophysiology of ischaemia heart disease 
Ischaemic heart disease, also known as coronary artery disease, is the most common cause of 
heart failure in the developed world.(9,10) Atherosclerosis plays an important 
pathophysiological role in the development of IHD (Figure 1-1).(11,12) 
Atherosclerosis involves the remodelling of the arterial wall with the accumulation of sub-
endothelial lesions called atherosclerotic lesions or plaques. The pathogenesis of 
atherosclerosis involves endothelial dysfunction, vascular inflammation and the deposition of 
lipids, calcium and cellular debris within the tunica intima, the innermost wall of the blood 
vessel.(13)  Endothelial dysfunction occurs due to presence of several risk factors such as 
dyslipidaemia, hypertension, hyperglycaemia and inflammation, all of which lead to an 
increased expression of cell adhesion molecules and structural changes, particularly vascular 
cell adhesion molecule 1 (VCAM-1), which allows platelet activation and infiltration by 
leucocytes and low density lipoproteins (LDL).(12,14,15) LDL is oxidised in the presence of 
reactive oxygen species (ROS) and other oxidative pathways, which are then ingested by 
macrophages to become foam cells.  
Foam cells release chemical signals, or cytokines, exacerbating the inflammatory response. 
This causes chronic inflammation and proliferation of the plaque by recruitment of 
inflammatory cells, lipids and LDL, migration of smooth muscle from the tunica media and 
further activation of the endothelium.(14,15)  
The atherosclerotic plaque is composed of a necrotic lipid-rich core, inflammatory cells such 
as foam cells, smooth muscle cells, and calcium deposits. With ongoing chronic inflammation, 
the plaque develops fibrous tissue and an overlying fibrous cap which can cause stenosis or 
narrowing the lumen of the artery.(15) Proliferation of the plaque narrows the lumen of the 
artery, reducing the blood supply. Consequently there is insufficient oxygen supply to the 




Figure 1-1: Pathogenesis and complications of IHD. 
The development of atherosclerosis occurs in the presence of various risk factor. Progression 
of atherosclerosis can cause obstruction of the lumen of the artery, or more severely, lead to 
plaque rupture and thrombus formation causing acute coronary syndromes. NSTEMI, non-ST 
elevation myocardial infarction; STEMI, ST elevation myocardial infarction. 
 
Complications of IHD may manifest as symptoms and signs of varying severity. Stable 
angina is characterised by episodes of ischaemia induced by increased myocardial demand, as 
in exercise or stress causing chest pain, usually caused by stenosis. Unstable angina is 
characterised by ischaemia at rest or minimal exertion.(16,17) Acute coronary syndrome 
(ACS) is a major complication of IHD, most commonly caused by rupture of the fibrous cap 
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includes unstable angina, or MI. MI is characterised by death of the cardiac muscle tissue or 
myocardial necrosis due to ischaemia.(17) Partial, transient occlusion of the artery causes 
unstable angina or non-ST elevation MI (NSTEMI), while complete occlusion of the artery 
causes ST elevation MI (STEMI). NSTEMI and STEMI are characterised based on the 
changes seen in electrocardiography (ECG) at diagnosis.(17) 
Following MI, pathophysiological mechanisms lead to myocardial dysfunction associated 
with ischaemia, metabolic changes and inflammation. Due to a decrease in oxygen supply, the 
metabolism of the heart shifts from an aerobic to anaerobic state, which significantly reduces 
energy/adenosine triphosphate (ATP) production and consequently lactate is produced, 
resulting in the loss of cellular homeostasis.(18) The loss of cellular metabolism and 
ischaemic injury causes cell death by necrosis and apoptosis. Necrosis occurs due to the 
disruption of cellular processes and elicits an inflammatory response, while apoptosis is a 
programmed cell death mediated by molecular signalling.(19) Due to the changes in cellular 
metabolism and loss of functional cardiomyocytes, there is decreased cardiac function and 
contractility of the heart which is acutely compensated by the activation of the renin-
angiotensin-aldosterone system (RAAS), sympathetic innervation and production of 
natriuretic peptide (Figure 1-2).(18,20)  
The inflammatory response following MI leads to the recruitment of a cellular infiltrate of 
neutrophils followed by monocytes/macrophages, which clear cell debris and begins the 
remodelling process of the heart.(20) In early remodelling (within 72 hours of ischaemic 
injury), neutrophils degrade the extracellular matrix (ECM). This leads to ventricular dilation 
and wall thinning later on in the disease process, increasing wall stress on the ventricles.(20) 
In response to RAAS activation, wall stretch and paracrine factors, late remodelling processes 
(after 72 hours of ischaemic injury) occur including hypertrophy of non-infarcted myocytes, 
formation of blood vessels by angiogenesis and collagen deposition and scar formation by 
myofibroblasts.(20) 
1.1.2 Heart failure 
Due to the limited regenerative capacity of the heart, the infarcted tissue is repaired by 
fibrosis, accompanied ventricular dilation and hypertrophy which alters the structural integrity 
of the heart. The extent of the remodelling process is correlated with infarct size, and is 
associated with functional consequences such as increased mortality, worse prognosis and 




Figure 1-2: Vicious cycle of heart failure. 
Compensatory mechanisms improve cardiac function in the short term. These mechanisms 
cause ventricular dysfunction in the long term causing a progressive loss of cardiac tissue, and 
deterioration cardiac function. RAAS, renin-angiotensin-aldosterone system. 
 
HF is an end-stage complication of IHD and is characterised by structural or functional 
abnormalities causing reduced cardiac output or elevated intracardiac pressures. HF is 
associated with typical symptoms and signs including breathlessness, oedema, fatigue and 
increased jugular venous pressure.(21) There is a progression in the severity of HF 
represented as a vicious cycle (Figure 1-2).(10,22) Impaired ventricular function reduces 
cardiac output. Compensatory mechanisms such as activation of the sympathetic nervous 
system and activation of the RAAS are activated in response to decreased cardiac output. This 
causes increased heart rate, systemic vasoconstriction and salt and water retention to improve 
cardiac function in the short-term. However, the persistent increase in wall stress due to 
Ventricular dysfunction
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• Decreased renal perfusion
Increased ventricular wall 
stress
• Increased vascular 
resistance (afterload) 
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increased ventricular filling volumes, increased oxygen demand due to increased heart rate 
and the ongoing ventricular remodelling, subsequent ventricular dysfunction occurs further 
reducing the cardiac output. Current available treatment slows progression of HF by targeting 
mechanisms in this ‘vicious cycle’ but does not address the underlying pathology of lost 
cardiac tissue causing functional depression of the heart. 
1.1.3 Current interventions for IHD 
Primary prevention of CVD involves interventions to manage risk factors at both individual 
and population levels to prevent the development of CVD. While these interventions have 
reduced CVD associated mortality rates, CVD still remains the leading cause of death 
worldwide.(1,23) 
Management of IHD involves lifestyle modification and pharmacological intervention to 
control for modifiable risk factors to reduce symptoms and improve prognosis.(16) 
Modifiable risk factors include smoking, diet, physical activity and management of co-
morbidities associated with IHD such as dyslipidaemia, hypertension, diabetes mellitus (DM), 
and chronic kidney disease (CKD). Lifestyle modifications include reduced exposure to and 
cessation of smoking, a healthy diet including decreased intake of saturated fat, salt and 
alcohol, regular physical activity (30 minutes per session, ≥3 times a week of moderate 
intensity), maintaining or achieving or normal body mass index.(16)  Pharmacological 
interventions to manage risk factors include lipid-lowering drugs such as statins to manage 
dyslipidaemia and LDL cholesterol, anti-hypertensive drugs such as thiazides, β-blockers and 
angiotensin converting enzyme inhibitors (ACE-I) to reduce blood pressure to recommended 
levels (<140/90 mmHg) and for individuals with DM, controlling glucose levels and glycated 
haemoglobin (HbA1c) (<48-52 mmol/mol).(16) 
In the event of an acute MI, time to reperfusion is an essential prognostic factor for the 
outcome of treatment. Reperfusion is a treatment for restoring blood flow through or around a 
blocked artery. Reduced time to perfusion is associated with reduced mortality and infarct 
size. Current reperfusion strategies address the importance of reducing the time to 
reperfusion.(24) Percutaneous coronary intervention (PCI) and fibrinolysis and, in patients 
who do not respond coronary artery bypass grafting (CABG) surgery, are indicated as 
reperfusion/revascularisation strategies of NSTEMI and STEMI.(17,25) 
Post-MI treatment involves cardioprotective interventions and secondary prevention of further 
complications of IHD.(26) Lifestyle changes and pharmacological therapy, including anti-
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platelet and anti-coagulant agents to prevent thrombus formation, reduce the risk of further 
complications and progression of ventricular dysfunction. Revascularization may be indicated 
in patients with haemodynamic instability by PCI or CABG surgery.(17,26) 
The treatment of heart failure aims to improve cardiac function and the patient’s quality of 
life, relieve symptoms, prevent progression of the disease and reduce mortality.(21) 
Treatment involves improving haemodynamic parameters including ejection fraction, cardiac 
output and fluid dynamics through various pharmacological interventions. For heart failure 
which cannot be stabilised by medical therapy, ventricular assist devices (VAD) are indicated 
as a bridge-to-transplantation therapy for patients awaiting heart transplantation.(21) VADs 
are mechanical devices that support cardiac function and is an elective surgical treatment. 
VADs are not viable for long-term use and are associated with major complications such as 
mechanical failure and death.(27) For end-stage heart failure, the current treatment options are 
orthotopic heart transplantation, VADs and palliative care.(21) Due to the strict eligibility 
criteria, limited availability of donor hearts for heart transplantations and the risk of immune 
rejection, this treatment option is not viable for many patients. Despite the number of 
available treatment options described above, there is no treatment option that addresses the 
loss of cardiac tissue in IHD, HF and following a MI. Hence, there is considerable interest in 
new strategies that promote repair and regeneration of cardiac tissue. 
 
1.2 Stem cell therapy for cardiac repair 
Regenerative therapy using stem cells provides a promising adjunct to current treatment with 
the potential to facilitate regeneration and repair of cardiac tissue by transplantation of stem 
cells. Current challenges in cell therapy include identifying the ideal stem cell source, optimal 
delivery method and improving cell survival, retention and engraftment of stem cells into 
cardiac tissue.(28,29)  
Stem cells are defined as undifferentiated cells that can self-renew and have the potential to 
differentiate into multiple cell lineages, which is known as potency. Progenitor cells are 
lineage-specific with a more limited differentiation potential and proliferate for a finite 
number of divisions.(30,31) Embryonic stem cells (ESC) derived from the inner cell mass of 
an embryo and induced pluripotent stem cells (iPSC) produced by reprogramming somatic 
cells, are pluripotent cells meaning they can differentiate into the cells of the three germ 
layers: ectoderm, mesoderm and endoderm.(32) ASCs derived from somatic tissue are 
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multipotent cells that can differentiate into multiple lineages but have a more limited 
differentiation capacity.(33) For the successful regeneration of the heart, it is essential to 
identify stem cells which can differentiate into cardiomyocytes, endothelial cells and smooth 
muscle cells. 
Stem cells have been transplanted into the heart by intracoronary infusion or direct 
intramyocardial injection, though these delivery routes are associated with limitations.(30) An 
optimal route of delivery would ensure that sufficient number of stem cells reach the target 
site, have little to no risk of off-target effects and haematological dissemination, and be 
minimally invasive.(3) Another limitation of stem cell therapy is the low retention of stem 
cells following transplantation.(28,30) Transplanted stem cells are subjected to the hostile 
environment of ischaemic tissue characterised by hypoxia, acidosis, inflammation and 
oxidative stress.(28,30) Current strategies under investigation include pre-treatment of target 
tissue, pre-treatment of cells and tissue engineering to improve cell survival and engraftment 
into cardiac tissue.(33) 
Pluripotent stem cells have only just begun progressing towards clinical trials, and there is 
concern about their safety and complications for transplantation in human studies.(34,35) 
There have been considerable clinical trials using ASCs which have demonstrated safety, 
particularly with autologous transplantation, and evidence for improvements in cardiac 
function and reduction in the remodelling process in post-MI.(36) Currently, ASCs seem to be 
much more appealing due to their safety compared to pluripotent cells.  
The ideal stem cell candidate, or combination of cells, for cardiac repair should be easy to 
expand in vitro, allow autologous transplantation, facilitate cardiomyogenesis (regeneration of 
cardiomyocytes) and neovascularisation (formation of new blood vessels), and differentiate 
into cardiac lineages with minimal limitations and complications.(29) 
 
1.3 Pluripotent stem cells 
1.3.1 Embryonic stem cells 
ESCs are typically derived from the inner cell mass of blastocysts which develop from unused 
embryos generated from procedures such as in vitro fertilisation.(37) Due to their potential to 
give rise to all cell types of the body, ESCs have a therapeutic potential for several medical 
conditions of different body systems. 
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ESCs have been shown to develop into an foetal liver kinase 1 (Flk1) positive and islet 1 
(Isl1) positive CPCs which are present in the early mesoderm during development specific to 
cardiac lineages which in turn are capable of differentiating into cardiac lineage cells.(38,39) 
Human ESC-derived cardiomyocytes have been shown to regenerate non-human primate 
hearts.(40) 
However, there are significant limitations to the use of ESCs. Transplantation of 
undifferentiated human ESCs can cause formation of a teratoma, a heterogeneous tumour 
containing cells derived from all three germ layers, in mice.(41) Transplantation of ESCs may 
cause immune rejection.(42) To reduce the consequences of immune rejection of ESCs, 
immunosuppressive drug regimens and histocompatibility matched ESCs may be used but are 
clinically challenging.(42,43) To obtain ESCs from the inner cell mass, the embryo is 
destroyed in the process which raises some ethical and legal concerns.(44) 
1.3.2 Induced pluripotent stem cells 
The recent discovery of iPSCs is an alternative pluripotent cell to ESCs. iPSCs were first 
discovered by introducing transcription factors including octamer-binding protein 3/4 (Oct-
3/4), sex determining region Y box 2 (SOX2), Myc proto-oncogene protein (c-Myc) and 
Kruppel-like factor 4 (KLF4) into adult mouse fibroblasts using retroviral vectors.(45) Human 
fibroblasts were later used to generate iPSCs using a similar method.(46) All four 
transcription factors described above are important in maintaining pluripotency, cell 
phenotype and rapid proliferation of ESCs. iPSCs have similar characteristics to ESCs with 
the ability for unlimited self-renewal and pluripotency, although there are subtle differences 
which may limit their therapeutic potential.(32,47)  
The reprogramming of somatic cells derived from a patient could allow for patient-matched 
autologous transplantation, eliminating the concern regarding immunogenicity.(32,48) As the 
generation of iPSCs does not involve the use of embryos, it has less ethical implications 
compared to ESCs. iPSCs have a promising potential for regenerative medicine though there 
are challenges that need to be addressed before they can be translated for clinical applications 
The potential for teratoma formation still remains a concern in iPSCs, which may be more 
tumorigenic, similar to ESCs.(49,50) Another limitation is that inducing pluripotency could 




1.4 Adult stem cells 
Adult stem cells are cells derived from adult somatic tissue and are a readily available source 
of stem cells. Various populations of ASCs have been characterised for their potential for 
cardiac regeneration including skeletal myoblasts, bone marrow derived cells, endothelial 
progenitor cells (EPC), mesenchymal stem cells (MSC) and cardiac stem/progenitor cells. 
They provide several advantages over pluripotent stem cells as they allow autologous 
transplantation, are readily available following isolation, relatively safe and are not associated 
with ethical constrictions. 
1.4.1 Skeletal myoblasts 
Skeletal myoblasts are one of the most extensively studied ASCs for cardiac repair in patients 
with IHD. Skeletal myoblasts are suitable for cardiac repair due to their myogenic 
differentiation potential that can form contractile elements in the heart.(51) Various studies 
have shown improvements in cardiac function following transplantation of skeletal 
myoblasts.(52–54) However the myoblast autologous grafting in ischaemic cardiomyopathy 
(MAGIC) trial, a large scale randomised placebo-controlled phase 1 clinical trial of myoblast 
transplantation showed no significant improvement in heart function following transplantation 
of skeletal myoblasts over CABG surgery.(55) Moreover, another study showed that skeletal 
myoblasts are restricted to the myogenic lineage and cannot differentiate into cardiomyocytes. 
Importantly they were unable to integrate electromechanically into the myocardium, 
increasing the risk to cause arrhythmias.(51) 
Several mechanisms have been proposed for the generation of arrhythmia. Connexin 43, a gap 
junction protein, and N-cadherin, an adhesion protein, are essential for electrical-mechanical 
coupling and forming intercalated discs with cardiomyocytes to allow synchronous 
contraction.(56) Connexin 43 and N-cadherin are not expressed in differentiated skeletal 
myoblasts. Overexpression of connexin 43 in skeletal myoblasts improved electrical coupling 
with cardiomyocytes in vitro and in vivo.(57,58) However, in a study by Fernandes et al. 
overexpression of connexin 43 did not significantly decrease arrhythmia following myoblast 
transplantation in vivo.(59) Further studies are therefore required to determine the 
applicability and feasibility of overexpression of connexin 43. 
1.4.2 Bone marrow derived cells 
The bone marrow contains a reservoir of haematopoietic and non-haematopoietic stem cells. 
Due to their ease of accessibility and being abundantly available, bone marrow derived cells 
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(BMDC) do not require extensive ex vivo manipulation.(29,60) Orlic et al. first demonstrated 
regeneration of the infarcted myocardium by transplantation of BMDCs expressing the stem 
cell marker, proto-oncogene c-Kit (c-Kit), through differentiation into cardiomyocytes, 
smooth muscle cells.(61) However, other studies have demonstrated that BMDCs do not 
transdifferentiate into cells of the cardiac lineage.(62,63) The efficacy and safety of BMDCs 
has been demonstrated in a number of clinical studies.(60,64,65) 
Bone marrow mononuclear cells (BMMC) are an unselected heterogeneous population of 
stem cells composed of haematopoietic stem cells (HSC), EPCs and MSCs, among 
others.(33,60) Therapeutic effects of BMMCs were shown in the reinfusion of enriched 
progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI), a 
randomised placebo-controlled study of intracoronary infusion of BMMCs which showed 
marked improvements in left ventricular function in patients infused with BMMCs.(66) 
HSCs isolated from the bone marrow are multipotent stem cells that can give rise to all 
haematopoietic lineages. Subpopulations of such cells have been isolated from the bone 
marrow expressing haematopoietic cell markers (cluster of differentiation, CD) such as CD34 
and CD133 (formerly known as AC133), which have been shown to promote 
angiogenesis.(60,67) 
EPCs are a subset of HSCs involved in post-natal neovascularisation.(68) EPCs can be 
isolated from the mononuclear cells of the bone marrow, peripheral blood and umbilical cord 
blood.(69,70) EPCs are characterised by the expression of a haematopoietic stem cell marker 
such as CD34 and CD133 and an endothelial cell marker such as vascular endothelial growth 
factor receptor (VEGFR) or CD31.(71) EPCs can differentiate into mature endothelial cells 
and are thought to be involved in vascular repair following injury.(71) Due to their ease of 
accessibility and beneficial effects on neovascularisation, EPCs hold promise for vascular 
diseases such as peripheral artery disease and IHD.(72) 
EPCs can be classified into either; early EPCs and late or outgrowth EPCs. Early EPCs appear 
4 to 7 days after culturing mononuclear cells and late EPCs appear after 14 to 21 days of 
culture and form cobblestone-shaped colonies, the typical appearance of mature endothelial 
cells.(71) Early EPCs have been shown to augment angiogenesis through paracrine 
mechanisms but do not directly incorporate into the vasculature while late EPCs have been 
shown to incorporate into the vasculature but do not exert paracrine mechanisms for 
angiogenesis.(73,74) These distinct differences in angiogenic effects can be utilised for their 
therapeutic roles in neovascularisation. 
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1.4.3 Mesenchymal stem cells 
MSCs are multipotent cells distributed throughout the body that can differentiate into 
mesodermal lineages including chondrocytes, adipocytes and osteoblasts. MSCs derived from 
the bone marrow (BM-MSC) and adipose tissue (Ad-MSC) being the most investigated.(75) 
MSCs isolated from umbilical cord (UC-MSC), specifically from the Wharton’s jelly and 
cord blood have recently gained interest, due to their higher proliferative potential, ability to 
self-renew and lower immunogenicity.(76,77) 
Due to the heterogeneity of MSCs, it is difficult to classify these cell as they lack a unique 
cell marker. The following criteria established by the International Society of Cellular 
Therapy that outlines the minimal requirements to classify MSCs.(78) MSCs must: be 
adherent to plastic when cultured under standard conditions; express mesenchymal cell 
surface markers including CD105, CD73 and CD90 while lacking the expression of cell 
markers for CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR; be able to 
differentiate into mesodermal lineages. 
MSCs have potent immunomodulatory properties by suppressing white blood cells and 
triggering an anti-inflammatory response.(75) In the phase 1/2, percutaneous stem cell 
injection delivery effects on neomyogenesis (POSEIDON) trial comparing allogenic and 
autologous BM-MSC in patients with left ventricular dysfunction due to ischaemic 
cardiomyopathy, MSCs showed low rates of adverse events including immune rejection, 
suggesting the use of MSC for allogenic transplantation possible through their 
immunomodulatory effects.(79) 
In the phase 1/2 placebo-controlled, prospective randomised study of mesenchymal stem cell 
therapy in patients undergoing cardiac surgery (PROMETHEUS) trial, left ventricular 
ejection fraction (LVEF) increased and scar size was reduced in patients receiving 
intramyocardial injections of autologous MSCs, demonstrating the efficacy and safety of 
MSCs.(80) 
1.4.4 Cardiac stem/progenitor cells 
The heart was once thought to be a post-mitotic organ without the ability to regenerate 
following ischaemic injury. However, the demonstration of the presence of replicating 
cardiomyocytes in the heart and the discovery of CSCs have led to a paradigm change.(81,82) 
CSCs in the adult heart are involved in limited cell turnover and endogenous cardiac 
regeneration. Low rate of cardiomyocyte renewal (up to 1.9%) has been observed in hearts of 
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young human adult at 20 years of age.(83) Furthermore, following ischaemic injury, 
cardiomyocytes are renewed by stem/progenitor cells.(84) The emerging concept of CSCs and 
their availability in the adult heart for autologous transplantation has elicited overwhelming 
interest and investigation of these cells. Due to the specific role of CSCs in endogenous 
cardiac repair and cardiac development, they hold great promise for the regeneration of 
cardiac tissue. 
Different populations of CSCs have been characterised in the heart, of which c-Kit+ cells and 
cardiosphere-derived cells (CDC) have been the most extensively studied to date.  
1.4.4.1 C-Kit+ cells 
CSCs were first identified in the rodent heart by the expression of the cell surface marker c-
Kit, a common stem cell marker, but negative for haematopoietic lineage markers (Lin-), 
known as c-Kit+ cells.(81) 
Stem cell infusion in patients with ischaemic cardiomyopathy (SCIPIO) was the first 
randomised phase 1 clinical trial involving the administration of autologous c-Kit+ cells in 
patients with severe ischaemic cardiomyopathy.(85) C-Kit+ cells were isolated and expanded 
from the RAA of patients undergoing on-pump CABG surgery. Approximately 4 months after 
the surgery, c-Kit+ cells were administered to patients in the treatment group by intracoronary 
infusion in the infarcted regions. No adverse effects were reported in the c-Kit+ cell treated 
group. In the c-Kit+ cell treated group, LVEF increased from 30.3% before infusion to 38.5% 
4 months following infusion (p=0.001). In contrast, LVEF did not change during the 
corresponding time points in the control group which did not receive the stem cell infusion. 
The beneficial effects of c-Kit+ cell infusion was more pronounced following 1 year after 
infusion which was associated with a decrease in the infarct size.  
Despite these promising results, there has been controversy of the nature of c-Kit+ cells. 
Sultana et al. states that c-Kit+ cells are actually a population of endothelial cells in the heart 
rather than resident CSCs.(86) In another study, c-Kit+ cells were shown to have a limited 
potential to differentiate into cardiomyocytes in mice during aging and after an injury.(87) 
Nevertheless, the potential benefits from these cells should not be ignored. 
1.4.4.2 Cardiosphere-derived cells 
CDCs are another type of stem cell from the heart that are extensively studied. CDCs are a 
heterogeneous population of cardiac cells isolated from cardiospheres, which are cell 
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aggregates that form when myocardial tissue explants are cultured under specific 
conditions.(88)  
A phase 1 cardiosphere-derived autologous stem cells to reverse ventricular dysfunction 
(CADUCEUS) trial, in which patients with recent MI with a LVEF of 25-45% and had 
undergone successful PCI treatment were randomised into the treatment group receiving 
autologous CDC transplantation and the control group receiving standard treatment.(89) In 
the CDC treated group, CDCs were isolated from right ventricular endomyocardial biopsies 
of patients and then infused into an artery related to the infarct area. There were no significant 
differences in LVEF between patients receiving CDC infusion and patients receiving standard 
care. However, patients receiving CDC transplantation showed a reduction in infarct size and 
improved regional contractility.(89) 
A study has directly compared the in vitro and in vivo functional effects of CDCs against BM-
MSCs, Ad-MSCs and BMMCs, the cells considered to be the most promising for cardiac 
repair.(4) Importantly, CDCs showed greater cardiomyogenic differentiation and angiogenic 
potential than other cell types in vitro, as well a balanced paracrine profile. When injected 
into the infarcted myocardium of mice, CDCs showed superior effects on cardiac repair 
including greater cell engraftment and in vivo differentiation, reduced apoptosis and reduced 
ventricular remodelling at 3 weeks post-MI. In addition, CDCs increased the LVEF and was 
the only group that showed significant improvement than the controls. Furthermore, unsorted 
CDCs had superior functional effects compared to purified c-Kit+ cells after transplantation 
into the infarcted heart.(4) This evidence along with the results from clinical trials suggest 
that CDCs are the leading contenders for the ideal stem cell source for efficient cardiac 
regeneration. 
1.4.4.3 Other cardiac stem cell populations 
Other endogenous CSC populations include stem cell antigen 1 (Sca-1+) cells and side 
population (SP) cells. Sca-1+ cells were first isolated from the adult murine heart which 
express early cardiac transcription factors.(90) SP cells are multipotent progenitor cells 
isolated from the heart characterised by their ability to exclude the Hoechst dye.(91) 
Recent genetic fate mapping studies in mice have revealed populations of progenitor cells that 
give rise to anatomically distinct areas of the heart.(92) Islet 1 (Isl1) is a cardiac transcription 
factor expressed in CPCs of the second heart field which contributes to the development of 
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the right ventricle, atria and outflow tract.(92)  Isl1+ cells have the ability to differentiate into 
cardiac lineage cells.(39)  
Epicardium-derived cells (EPDC) were identified in the epicardium, a layer of mesothelium 
covering the heart.(93) The epicardium originates from the proepicardium during 
development, distinct from the first and second heart field.(92) A subset of epicardial cells 
undergo epithelial-to-mesenchymal transition (EMT) during development and participate in 
the development of the myocardium.(93,94) EPDCs have been demonstrated to promote 
angiogenesis and are a promising candidate for cardiac repair.(95,96) 
 
1.5 Combination cell therapy using different adult stem cell populations for cardiac 
repair 
Since studies have identified functional differences across different stem cell populations, 
combination of cells that exert complimentary or synergistic effects may have the potential 
for greater therapeutic effects on cardiac repair than single cell populations. 
Early evidence for the clinical relevance of combination cell therapy for cardiac repair was 
shown using combined transplantation of skeletal myoblasts with BMMCs after myocardial 
infarction in rats.(97) 
Similarly, combined transplantation of skeletal myoblasts with CD133+ cells in a model of 
chronic IHD improved cardiac function, reduced scar size and apoptosis, and increased 
angiogenesis in rats.(98) Skeletal myoblasts improve cardiac function by introducing 
contractile elements, while CD133+ cells increase angiogenesis. The functional benefits of 
the combined transplantation were mainly attributable to the increased neovascularisation 
which improved the blood supply for the engraftment of the skeletal myoblasts.  
Following combined xenogeneic (from different species) transplantation of BM-MSCs with c-
Kit+ CSCs in a porcine model of MI improves cardiac function and enhances scar size 
reduction.(99) Another study showed combined autologous transplantation of BM-MSCs with 
CSCs in a porcine model of chronic IHD showed similar improvements in cardiac function 
and scar size reduction.(100) Combined transplantation of CSC/CPCs with saphenous vein 
pericytes and EPCs, both known for their role in neovascularisation, have reported 
improvements in cardiac function in a model of MI.(101,102) The effects of combination 
therapy have been attributed to complimentary or synergistic paracrine profiles of the 
different stem cell populations, enhancing the therapeutic potential of stem cells. 
16 
 
1.6 Paracrine mechanisms of cell therapy on cardiac repair 
Due to the multifunctional properties of stem cells, several mechanisms have been suggested 
to mediate their beneficial effects on cardiac repair (Figure 1-3). The major mechanisms of 
cell therapy include replacement of lost cardiac tissue by direct differentiation into functional 
cardiomyocytes, smooth muscle cells and endothelial and the release of paracrine factors that 
mediate responses in cardiac repair.(33)  
Initially, it was thought that differentiation of stem cells was responsible for improvements 
seen in cardiac function. Pluripotent stem cells and CSCs can differentiate into cells of the 
cardiac lineage, although the potential of other ASCs to differentiate into cells of the 
cardiovascular lineage remains highly controversial.(29,33) Additionally, the functional 
improvements following stem cell transplantation is not sufficiently explained by 
differentiation due to the relatively small number of new cardiomyocytes formed.(7,33) This 
has led to a paradigm change and it is now believed that the majority of the therapeutic effects 




Figure 1-3: Potential mechanisms involved in stem cell therapy. 
Differentiation and paracrine effects are the major mechanisms involved in the regenerative 
effects of stem cell therapy. The release of paracrine factors from transplanted stem cells are 
thought to mediate the major responses in cardiac repair through paracrine and autocrine 
effects. 
 
Paracrine factors released by stem cells after transplantation play an essential role in the 
reparative process of cell therapy. The paracrine mechanism supports the regenerative process 
by promoting cardioprotection, neovascularisation, immunomodulation and stimulating 
endogenous stem cells.(33) Of these, cardioprotection and neovascularisation have been the 
most studied.(7) ASCs secrete a variety of different growth factors, cytokines, chemokines, 
microvesicles and exosomes to mediate cardiac repair.(7,105) Microvesicles and exosomes 
are secreted membrane vesicles containing lipids, protein and nucleic acids such as messenger 
ribonucleic acid (mRNA) and microRNA (miR), involved in cell-cell communication.(105) 
Prominent paracrine factors secreted by ASCs include insulin-like growth factor 1 (IGF-1), 


















growth factor (bFGF), erythropoietin (EPO), platelet derived growth factor (PDGF), 
angiopoietins (ANG), and interleukins (IL), among others.(7,106) 
Furthermore, the microenvironment of stem cells influences the release of such factors, as in 
IHD where the ischaemic environment promotes the release of paracrine factors.(103) In 
addition, secreted factors exert autocrine effects on the stem cells themselves which affect 
their cell survival, growth and self-renewal properties.(7,106) 
1.6.1 Cardioprotection 
In the infarcted heart, cell death results from necrosis and apoptosis.(19) Transplantation of 
stem cells have protective effects on the myocardium and attenuate ischaemic/reperfusion 
injury, reduce apoptosis and increase proliferation of cardiomyocytes. (7,106) 
ASCs such as HSCs, MSCs and CSC/CPCs have been shown to exert anti-apoptotic effects 
through paracrine-mediated mechanisms.(107–109) Secreted factors by CDCs reduced 
apoptosis on neonatal rat ventricular myocytes in vitro.(110) Similarly, when CDCs were 
transplanted into murine model of MI, resulting in decreased apoptotic rate at the peri-infarct 
border.(110) 
Cardioprotective effects exerted by paracrine factors are mediated through the activation of 
several pro-survival pathways (Figure 1-4).(7,111–113) Most paracrine factors released by 
stem cells activate the reperfusion injury salvage kinase (RISK) pathway which activate the 
kinases AKT and extracellular signal-regulated kinase 1/2 (ERK-1/2) through 
phosphatidylinositol 3-kinase -AKT (PI3K/AKT) and mitogen-activated protein kinase 1/2 -
ERK-1/2 (MAPK/ERK) signalling.(7,111) Other pathways that are implicated in 
cardioprotection include survivor activating factor enhancement (SAFE) which activates the 
signal transducer and activator of transcription 3 (STAT3) through Janus kinase -STAT 
(JAK/STAT) signalling, and the protein kinase C epsilon (PKCε) pathway.(7,112) These 
pathways act through various mechanisms to exert cardioprotection including direct anti-
apoptotic effects, regulation of gene expression and inhibition of mitochondrial permeability 




Figure 1-4: Cell signalling pathways involved in cardioprotection.  
Various paracrine factors (growth factors, cytokines and chemokines) bind to specific cell 
receptors to exert cardioprotective effects through cell signalling pathways including the 
RISK pathway, SAFE pathway and PKCε pathway. RISK, reperfusion injury salvage kinase; 
SAFE, survivor activating factor enhancement; PI3K/AKT, phosphatidylinositol 3-kinase -
AKT; MAPK/ERK, mitogen-activated protein kinase 1/2 -extracellular signal-regulated 
kinase 1/2; JAK/STAT, Janus kinase -signal transducer and activator of transcription factor; 
PKCε, protein kinase C epsilon; IGF-1, insulin-like growth factor 1; VEGF, vascular 
endothelial growth factor; EGF, epidermal growth factor; TNF, tumour necrosis factor; IL, 
interleukin; bFGF, basic fibroblast growth factor; EPO, erythropoietin; PI3K, 
phosphatidylinositol 3-kinase; JAK, Janus kinase; ERK1/2, extracellular signal-regulated 
kinase 1/2; STAT3, signal transducer and activator of transcription factor 3; mPTP, 



























Paracrine factors induce neovascularisation and the formation of new blood vessels. Restoring 
the blood supply to the ischaemic area is essential to reduce the extent of damage. The 
mechanisms involved in neovascularisation include: angiogenesis which is the sprouting and 
proliferation of endothelial cells from pre-existing vessels; vasculogenesis which is the 
formation of new vessels by fusion and differentiation of stem cells; arteriogenesis which 
involves the increase in arterial diameter of pre-existing vessels and formation of collateral 
circulations.(114,115) 
Stem cells secrete angiogenic and arteriogenic factors such as VEGF, bFGF, IL-6, HGF, 
ANG, placental growth factor (PLGF), among others, which have been implicated in 
neovascularisation.(106,116) Of these, VEGF and bFGF are the most potent angiogenic 
factors.(117) In addition to the aforementioned factors, EPCs express endothelial nitric oxide 
synthase (eNOS) and inducible nitric oxide synthase (iNOS) and secrete nitric oxide (NO) 
which contribute to neovascularisation.(118) 
1.6.3 Immunomodulation 
Following ischaemic injury, changes in the microenvironment make it hostile to cells, limiting 
the engraftment of transplanted stem cells. The release of paracrine factors by stem cells can 
modulate inflammatory and remodelling processes associated with ischaemic injury 
establishing a more favourable microenvironment for transplantation.(7,106) This process is 
well demonstrated in MSCs which secrete various factors to modulate inflammatory cells, 
anti-fibrotic and anti-inflammatory effects.(119,120)  
1.6.4 Stimulating/recruiting endogenous stem cells 
Cell therapy has been suggested to mobilise and recruit endogenous and circulating 
stem/progenitor cells to the site of injury to mediate cardiac repair.(7,106) Studies have 
shown that transplantation of stem cells can stimulate, recruit and activate of endogenous 
CSC/CPCs.(121–123) ASCs are known to secrete stromal cell-derived factor 1 (SDF-1), a 
chemokine involved in mobilisation and recruitment of BMDCs into the peripheral blood 
with subsequent homing to the site of injury.(124) 
1.6.5 Effect of hypoxic preconditioning 
Hypoxic preconditioning can promote cell survival of stem cells, reduce apoptotic cell death 
and increase angiogenesis through upregulation of various paracrine factors through the 
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transcriptional activity of hypoxia inducible factor 1 (HIF-1).(109,125–127) HIF-1 increases 
the expression of various paracrine factors including VEGF, EPO, ANG, PDGF, and 
bFGF.(128–130) 
HIF-1 is a transcription factor which plays an important role in the cellular response and 
adaptation to ischaemia/hypoxia.(130) HIF-1 is a heterodimer composed of an alpha and beta 
subunit. In normal oxygen conditions, proline residues on the hypoxia inducible factor 1 alpha 
(HIF-1α) are hydroxylated by HIF prolyl-hydroxylases utilising oxygen as a co-substrate with 
subsequent degradation by proteasomal pathways. In hypoxic conditions, HIF-1α is stabilised 
due to the lack of oxygen and the transcriptional action of HIF-1 on hypoxia response 
elements is increased which mediate cellular responses to hypoxia. HIF-1α can be stimulated 
by various hypoxia-independent pathways including the PI3K/AKT and PKCε signalling 
which may be of therapeutic relevance to stem cell therapy.(131,132) 
 
1.7 Differences in right atrial appendage and left ventricle cardiac progenitor cells 
Recently it was shown that CPCs derived from different sources of the heart from the same 
patients exhibited different functional and paracrine properties in vitro.(8) Conditioned media 
(CM) from LV CPCs demonstrated superior angiogenic effects on human umbilical vein 
endothelial cells (HUVEC), while CM from RAA CPCs demonstrated superior 
cardioprotective effects on HL-1 cardiomyocytes by reducing apoptosis and increasing 
proliferation.(8) CPCs used in this study represent a heterogeneous population of CPCs, 
predominantly expressing mesenchymal cell markers CD90 and CD105. Interestingly, LV 
CPCs showed a superior angiogenic effect compared to EPCs which are a leading cell source 
for neovascularisation.(8) The exact reason for these functional reasons are not known 
although may be due to the distinct functional and developmental characteristics, as well as 
the different microenvironments, of CPCs from different heart chambers. 
Atrial and ventricular cardiomyocytes have functional differences, both in 
electrophysiological and contractile properties due to differences in gene expression, and 
morphological and molecular characteristics.(133) During cardiac development, heart 
chambers arise from distinct regions or cell populations known as the first and second heart 
fields. The right atrium develops from both the first and second heart fields, while the left 
ventricle (LV) develops from the first heart field.(92) The microenvironment, or niche, of 
stem cells influence the function and characteristics of stem cells.(134,135) Furthermore, the 
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ischaemic microenvironment may influence the epigenetic status of cells.(136,137) Therefore 
in patients with IHD, the LV which is often subject to the hostile ischemic microenvironment 
may influence the functional effects and paracrine profiles of LV CPCs through epigenetic 
modifications. As discussed, several mechanisms may underlie the functional differences 
between RAA CPCs and LV CPCs which warrants further investigation and may give insight 




1.8 Thesis rationale 
The promise of cell therapy for regenerating the functional capacity of the diseased has been 
shown in various pre-clinical and clinical studies. Although many stem cell populations have 
been studied, the ideal stem cell has yet to be identified. Cardiac stem cells are involved in 
heart development, cell turnover and endogenous repair following injury to the heart hence 
are contenders as the ideal stem cell type. Furthermore, combination of different stem cells 
that have different reparative effects on the heart can be combined to further increase the 
efficacy of cell therapy. To date, there are no studies showing the combined effects of CPCs 
derived from different heart chambers of the same patient on cardiac repair. 
As CPCs derived from the RAA and LV exhibit functional differences in vitro, combination 
of these cells may increase the potential for cardiac repair by complimentary or synergistic 
effects. The different profiles of paracrine factors secreted into the CM by RAA CPCs and LV 
CPCs may further synergise, stimulate and enhance the secretome of one another.  
This study will evaluate the synergistic paracrine effects of a heterogeneous population of 
CPCs from the RAA and LV of the same patient on in vitro cardiac repair. RAA CPCs and 
LV CPCs will be cultured alone or in combination, in serum deprivation in normoxic and 
hypoxic conditions. CM collected following serum deprivation will be used for further in 
vitro experiments. The paracrine effects of CM on cardioprotection and angiogenesis will be 
measured to determine the synergistic paracrine effects of RAA CPCs and LV CPCs on 
cardiac repair. 
1.8.1 Aims 
• To determine if combination of RAA CPCs and LV CPCs provide synergistic 
paracrine effects to mediate cardioprotection and angiogenesis. 
• To explore possible mechanisms for synergistic paracrine effects of combination of 
RAA CPCs and LV CPCs. 
1.8.2 Hypotheses 
• Combination of RAA CPCs and LV CPCs will have equal or superior paracrine 
effects through complimentary or synergistic effects compared to single cultures. 
• Combination of RAA CPCs and LV CPCs may stimulate and enhance the paracrine 




2.1 Overview of methods 
 
Figure 2-1: Experimental study design. 
CPC, cardiac progenitor cell; RAA, right atrial appendage; LV, left ventricle; CABG, 
coronary artery bypass grafting; CM, conditioned media; ELISA, enzyme-linked 
immunosorbent assay. 
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2.2 Ethical approval 
The Heart Tissue Sample Study was ethically approved by the Lower South Regional Ethic 
Committee (ethics reference number: LRS/12/01/001). Patients were informed and consented 
to the study prior to obtaining tissue sample (Figure 2-2). 
 
 
Figure 2-2: Consent form patients signed prior to obtaining heart tissue samples. 
 
2.3 Tissue collection 
The RAA and LV were collected from patients (n=6) undergoing on-pump coronary artery 
bypass grafting (CABG) surgery at Dunedin Public Hospital. Patients with diabetes or 
undergoing adjunct valve replacement surgery were excluded from the study.  
Cardiac tissue was collected in Krebs Ringer Henseleit (KRH) solution, then transferred to a 




2.4 Cell culture 
All cell culture work was performed utilising aseptic technique in a laminar flow hood. Cells 
were checked daily by microscopic examination to determine confluency of the cells. Culture 
media was changed every 2-3 days or subcultured once confluent. 
2.4.1 Cardiac progenitor cells 
Cardiac progenitor cells were cultured in Ham’s F12 complete media containing Ham’s F12 
nutrient mixture (Gibco, USA) supplemented with 10 ng/mL human basic fibroblast growth 
factor (Sigma-Aldrich, USA), 0.005 U/mL human erythropoietin (EPO) (Sigma-Aldrich, 
USA), 10% foetal bovine serum (FBS) (Sigma-Aldrich, USA), and 1X antibiotic-antimycotic 
(anti-anti) (Gibco, USA). 
CPCs were cryopreserved using mesenchymal stem cell freezing media (Merck Millipore, 
USA). 
CPCs at passage 3 to 5 were used for experiments. 
2.4.2 AC16 cardiomyocytes 
AC16 cardiomyocytes (Merck Millipore, USA) are a proliferating human cardiomyocyte cell 
line derived from adult human ventricular cardiomyocytes, which were fused with SV40 
transformed, uridine auxotroph human fibroblasts devoid of mitochondrial DNA.(138) 
AC16 cardiomyocytes were cultured in Dulbecco’s modified eagle medium/F12 
(DMEM/F12) complete media containing DMEM/F12 media (Gibco, USA) supplemented 
with 12.5% FBS (Sigma-Aldrich, USA), and 1X anti-anti (Gibco, USA), according to the 
manufacturer’s protocol. 
AC16 cardiomyocytes were cryopreserved using DMEM/F12 complete media supplemented 
with 10 % dimethyl sulfoxide (DMSO). 
AC16 cardiomyocytes were used to determine the cardioprotective effects of CM. Cells from 
passage 22 to 23 were used for experiments (see chapter 2.9 and chapter 2.10). 
2.4.3 Human umbilical vein endothelial cells 
Human umbilical vein endothelial cells (ATCC, USA) were cultured in endothelial growth 
medium 2 (EGM-2) (Lonza, USA) containing endothelial basal medium 2 (EBM-2) 
supplemented with EGM-2 SingleQuots (Lonza, USA) which includes human Epidermal 
Growth Factor (EGF), vascular endothelial growth factor (VEGF), R3-insulin-like growth 
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factor-1 (R3-IGF-1) ascorbic acid, hydrocortisone, human bFGF, heparin, FBS, and 
gentamicin/amphotericin B (GA). 
HUVECs were frozen using EGM-2 complete media supplemented with 10% FBS (Sigma-
Aldrich, USA), and 10% DMSO. 
HUVECs at passage 4 and 5 were used for the tube formation assay to determine angiogenic 
effects of the CM (see chapter 2.11). 
2.4.4 Isolation of cardiac progenitor cells 
CPCs were isolated from the RAA and LV tissue through cell dissociation using collagenase 
II and subsequent seeding under specific culture conditions, as previously described.(8) 
Primary cells were not sorted and were selected based on specific culture conditions such as 
adherence to the culture dish in Ham’s F12 complete media, hence, represent a heterogeneous 
population of CPCs from the RAA and LV sample. A minimum of 10 mg of tissue was 
needed to isolate CPCs. Heart tissue was transferred to a 10-cm dish. Any adipose tissue was 
removed using scissors. The tissue was then washed twice with HBSS. To determine the size 
of the culture vessel for plating the cells, tissue was weighed. HBSS was added and the tissue 
was minced into smaller pieces. The tissue was then placed into a 15-mL tube and allowed to 
settle on ice. The supernatant was aspirated and fresh HBSS was added. Once the tissue 
settled, the supernatant was aspirated. 7 mL of 0.04% collagenase II solution (kept at 37°C) 
was added and transferred to a T25 flask. The tissue was incubated in a shaker-incubator set 
at 160 RPM at 37°C for 60 minutes. Following incubation, the solution was transferred to a 
15-mL tube and kept on ice to allow the tissue to settle. The supernatant was then collected in 
a fresh tube and kept on ice. 7 mL of fresh collagenase II solution (37°C) was added and 
mixed with the tissue by repetitive pipetting (x10) and allowed to settle on ice. The 
supernatant was collected once the tissue had settled and kept on ice. 
All steps after tissue dissociation were performed under sterile conditions in a laminar flow 
hood. The collected supernatant was centrifuged at 300 RCF for 5 minutes. Following 
centrifugation, supernatant was aspirated, and the cell pellet was loosened by gently tapping 
the bottom of the tube. The cell pellet was re-suspended in 1 mL Ham’s F12 complete media.  
Due to the variation in size between RAA and LV samples, cells were seeded onto an 
appropriately sized plate or flask based on the weight of the tissue to minimise differences in 
initial seeding density (Table 2-1). Obtaining a sufficient number of viable cells based on the 
size of the tissue was reproducible, which has been previously validated in the Katare 
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laboratory.(8) The cells were then incubated in a 5% CO2/95% air humidified incubator at 
37°C for 24 hours. Following 24 hours, cells were supplemented with fresh culture media. 
Thereafter, culture media was changed every 2-3 days or subcultured when the cells become 
90% confluent. 
 
Table 2-1: Table showing the appropriately sized culture vessels used to initially seed cells 
obtained from the heart tissue. 
Weight of the tissue (mg) Culture dish Total media volume 
10-30 12-well plate 1 mL/well 
30-60 6-well plate 2 mL/well 
60-150 T25 flask 
5 mL/flask 
150-300 2 x T25 flask 
 
RAA CPCs and LV CPCs were subcultured at the same time and at the same seeding density 
to ensure that cells remained in the same passage. RAA CPCs and LV CPCs showed similar 
proliferation rates hence reached confluency at a similar time. Due to the limited starting cell 
number following isolation, cell number was increased during the first few passages by 
increasing the size of the culture dish between passages. From passage 2 onwards, all CPCs 
were seeded onto T25 flasks. 
2.4.5 Initiation of frozen cells 
To initiate frozen CPCs and AC16 cardiomyocytes, the following protocol was used. Cells 
were quickly thawed in the water bath at 37°C. Once cells were thawed, 1 mL of the cell 
solution was transferred to a 15-mL tube. 9 mL of complete media was added by slow 
pipetting to prevent osmotic shock. Cells were then centrifuged at 300 RCF for 5 minutes. 
The supernatant was aspirated. The tube was tapped, and the cells were resuspended in 1 mL 
complete media. The cell solution was transferred to the relevant culture vessel then incubated 
for 24 hours. Following 24 hours, cells were supplemented with fresh culture media. 
2.4.6 Cryopreservation of cells 
To freeze CPCs and AC16 cardiomyocytes, the following protocol was used. The cell 
solution was centrifuged at 300 RCF for 5 minutes following trypsinisation. Supernatant was 
aspirated, and the cell pellet was loosened by gently tapping the tube. Cells were resuspended 
in freezing media and transferred to a freezing vial. The vial was placed in a cell freezing 
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container in a -80°C freezer for 24 hours. Following 24 hours, CPCs were stored at -80°C, 
and AC16 cardiomyocytes in liquid nitrogen at -196°C. 
2.4.7 Initiating HUVECs 
HUVECs were initiated from frozen aliquots. Prior to thawing cells, 5 mL EGM-2 complete 
media was added to T25 flasks and placed in a 5% CO2/95% air humidified incubator for 30 
minutes. Cells were quickly thawed in a 37°C water bath. Once thawed, 1 mL of the cell 
solution was transferred to the T25 flask prepared prior to thawing. Cells were then incubated 
for 24 hours. Following 24 hours, cells were supplemented with fresh culture media. 
2.4.8 Cryopreservation of HUVECs 
The cell solution was centrifuged at 200 RCF for 5 minutes following trypsinisation. 
Supernatant was aspirated, and the cell pellet was loosened by gently tapping the tube. Cells 
were re-suspended in HUVEC freezing media (5x105 to 2x106 cells/mL). The solution was 
transferred to a freezing vial and placed in a cell freezing container in a -80°C freezer for 24 
hours and then stored in liquid nitrogen at -196°C. 
2.4.9 Subculture 
The subculturing protocol between CPCs, AC16 cardiomyocytes and HUVECs differed with 
respect to the centrifugation, confluency at end of passage, seeding density and the culture 
vessel that was used to culture the cells (Table 2-2). 
 
Table 2-2: Table outlining differences in culture protocol of the different cell types. 





300 RCF for 
5 minutes 
300 RCF for 
5 minutes 
200 RCF for 
5 minutes 
Confluency at end of passage 90% 90% 80% 
Seeding density/split ratio 4,000 cells/cm2 Split ratio 1:6 3,000 cells/cm2 
Culture vessel T25 flask T75 flask T25 flask 
Total media volume 5 mL 10 mL 5mL 
RCF, relative centrifugal force; HUVEC, human umbilical vein endothelial cell. 
 
Once the cells reached confluency, cells were subcultured. Cells were washed with calcium 
and magnesium free phosphate buffered solution (PBS) (37°C) to remove any traces of serum, 
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calcium and magnesium which would inhibit the activity of the dissociation agent. PBS was 
pipetted carefully to the side of the culture vessel taking care not to disturb the cells, and the 
culture dish was gently rocked. PBS was then aspirated and discarded. TrypLE Express 
Enzyme (Gibco, USA) (80µL/cm2 of the culture vessel), a cell dissociation agent, was added 
to detach the cells. The culture vessel was gently rocked to cover the cell layer and then 
incubated at 37°C for 5 minutes. The culture vessel was tapped on the side and examined 
using the light microscope for cell detachment. If cells were less than 90% detached, the 
culture vessel was incubated for a further 1 minute and re-examined for cell detachment. 
Once cells were detached, complete media was added at a ratio of 2:1 (complete media: 
TrypLE) and mixed gently by pipetting to neutralise TrypLE. The cell solution was 
transferred to a sterile tube and centrifuged. The supernatant was then aspirated. The cell 
pellet was then re-suspended in 1 mL of complete media. Cells were counted using a 
haemocytometer. 10 μL of cell solution and trypan blue at a 1:1 ratio was added to the 
coverslip and counted. The required number of cells were seeded on to a culture vessel and 
incubated in a 5% CO2/95% air humidified incubator for 24 hours. After 24 hours, culture 
media was changed. 
 
2.5 Characterisation of CPCs using flow cytometry 
CPCs were characterised using flow cytometry for the expression of mesenchymal stem cell 
markers, CD90 (thymocyte differentiation antigen, Thy-1) and CD105 (endoglin, ENG), and 
the circulating haematopoietic progenitor cell marker CD34 as previously described.(8) 
CD90 is a heavily glycosylated glycoprotein involved in inflammation, wound healing and 
cell to cell and cell to matrix adhesion. (139) CD105 is a glycoprotein which interacts with 
transforming growth factor beta (TGF-β) receptor complex. It is also involved in cytoskeletal 
organisation, cell morphology and migration, and the development of the cardiovascular 
system.(139) CD34 is a transmembrane phosphoglycoprotein which is thought to be involved 




Figure 2-3: Diagram of the flow cytometer. 
Cells pass through in a single file by hydrodynamic focusing by the surrounding sheath fluid. 
As stained cells pass through the laser, the light is scattered in the forward (forward scatter), 
side (side scatter) directions. The conjugated fluorophore becomes excited by the laser which 
emits fluorescent light which is detected by the fluorescent light channels. 
 
Flow cytometry is a technique utilised for characterising cells by measuring the fluorescence 
emitted by fluorophores. Cells are stained with fluorophore-conjugated antibodies or ligands 
to specific cell markers which are then analysed using a flow cytometer. The flow cytometer 
allows single cell analysis by hydrodynamically focusing the cell suspension so that the cells 
pass through the laser one cell at a time (Figure 2-3). When the cell passes through the laser, 
light is scattered in various directions which is detected by various detectors known as 
phospho-multiplier tubes (PMT). The forward scatter (FSC) channel detects light scattered in 
the forward direction, while the side scatter (SSC) channels detect light scattered to the side 
Hydrodynamic focusing
















(90°). Forward scatter is proportional to cell size and side scatter is proportional to the 
granularity of the cell. Fluorophores re-emit fluorescent light when excited by a laser with the 
corresponding excitation wavelength, which is detected by fluorescent light (FL) channels. 
There are multiple FL channels which detect fluorescent light at different wavelengths. By 
utilising various fluorophores with different excitation and emission wavelengths, it is 
possible to analyse multiple cell markers on a per cell basis. 
2.5.1 Compensation control 
In multi-colour flow cytometry, the use of multiple fluorophores can cause detection of 
fluorescence outside of the respective FL channels. This is known as the spill-over effect. 
Therefore, single stained controls are used for compensating for these spill-over effects, 
controlling for the overlap between channels so that only the fluorophore of interest is 
detected in the respective channel. 
Antibody capture (AbC) beads (Invitrogen, USA) were used for compensation. Positive beads 
bind to all isotypes of mouse antibody, while the negative beads have no capacity to bind 
antibodies. Therefore, the use of beads allows clear discrimination between positive and 
negative populations. For compensation of propidium iodide (PI) (Invitrogen, USA) for cell 
viability, dead and live cells were used. 
2.5.2 Preparation of cells 
Cells were subcultured (see chapter 2.4.9). The cell pellet was loosened by gently tapping the 
tube and resuspending in 1 mL of Ham’s F12 complete media. Cells were counted using a 
haemocytometer. Following cell counting, cells were centrifuged at 300 RCF for 5 minutes. 
The supernatant was aspirated following centrifugation. The tube was gently tapped, and cells 
were resuspended in flow cytometry buffer consisting of HBSS supplemented with 3% FBS 
and 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). Cells were 
resuspended at a concentration of 6x105 to 6x106 cells/mL so that the final cell concentration 
for analysis was approximately 1x105 to 1x106 cells/mL (6-fold dilution). The ideal cell 
concentration for flow cytometry at data acquisition is 1x106 cells/mL. 
2.5.3 Preparation of samples for flow cytometry 
Flow cytometry samples were prepared in 5 mL round bottom polystyrene tubes (Corning, 
USA), according to the tube design shown in the following table (Table 2-3). 
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Table 2-3: Table showing the tube design for flow cytometry. 
Tube 
number 
Tube name Components 
1 Comp CD90 FITC AbC beads + FITC CD90 
2 Comp CD105 PE-Cy7 AbC beads + PE-Cy7 CD105 
3 Comp CD34 APC AbC beads + APC CD34 
4 Comp PI positive Dead cells + PI 
5 Comp PI negative Live cells + PI 
6 US1 RAA CPC RAA CPC 
7 FS1 RAA CPC RAA CPC + antibody solution + PI 
8 US2 LV CPC LV CPC 
9 FS2 LV CPC LV CPC + antibody solution + PI 
10 FMO FITC Cells + CD105 PE-Cy7 + CD34 APC + PI 
11 FMO PE-Cy7 Cells + CD90 FITC + + CD34 PE-Cy7 + PI 
12 FMO APC Cells + CD90 FITC + CD105 PE-Cy7 + PI 
13 FMO PI Cells + antibody solution + PI 
Comp, compensation; FITC, fluorescein isothiocyanate; PE-Cy7, phycoerythrin-cyanine7; 
APC, allophycocyanin; PI, propidium iodide; FMO, fluorescence-minus-one control; AbC, 
antibody capture. 
 
Fifty microlitres of the cell suspension (3x105 to 3x106 cells) was added to the appropriate 
tubes. Fifty microlitres of flow cytometry buffer was then added to each tube apart from the 
fully stained (FS) tubes.  Antibody solution was prepared by adding 2 µL each of CD90 FITC, 
CD105 PE-Cy7 and CD34 APC monoclonal antibody (eBioscience, USA) to 50 µL flow 
cytometry buffer per every tube that requires antibody solution. Fifty microlitres of the 
antibody solution was then added to the each of the FS tubes.  
The fluorescence-minus-one (FMO) controls were prepared by adding 50 μL of the cell 
solution to the appropriate tubes. For the FMO PI tube, 50 μL of antibody solution was added. 
For the other FMO tubes, an additional 50 μL flow cytometry buffer and 2 μL of the 
appropriate antibodies was added. 
For the compensation tubes, 1 drop of AbC beads (component A of anti-mouse AbC bead kit) 
was added. Thereafter, 2 µL of the appropriate antibody was then added to the compensation 
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tubes. For the PI compensation tubes, 50 µL of the cell solution and 50 µL of the flow 
cytometry buffer was added. The tubes were then incubated in the dark on ice for 30 minutes.  
The tubes were then incubated in the dark on ice for 30 minutes. For the PI positive tube, cells 
were incubated in a -80°C freezer for 30 minutes and thawed at room temperature to acquire 
dead cells prior to the wash step. 
To wash the tubes, 2 mL of flow cytometry buffer was added to the tubes containing cells and 
3 mL PBS was added to the tubes containing AbC beads. Tubes were then centrifuged at 300 
RCF at 4°C for 5 minutes. The supernatant was aspirated, and the wash step repeated for the 
tubes containing cells. One wash step is sufficient for the beads. Cells were then resuspended 
in 300 µL flow cytometry buffer and AbC beads resuspended in 300 µL PBS. One drop of 
negative beads (component B of anti-mouse AbC bead kit) were added to the tubes containing 
AbC beads. The samples were then vortexed briefly and stored on ice in the dark until data 
acquisition.  
Prior to data acquisition, 0.6 µL of PI (1.0 mg/mL, 1.5 mM) was added to the relevant tubes 
(final concentration 3 µM) and incubated for 15 minutes. 
2.5.4 Data acquisition 
Samples were briefly vortexed and loaded on to the Gallios flow cytometer (Beckman Coulter, 
USA). The corresponding fluorescent light (FL) channels to the fluorophores were included 
(Table 2-4). Prior to data acquisition, PMT voltages and gain were set to ensure cell 
populations were not off-scale and there was adequate separation between positive and 
negative cell populations. A minimum of 10,000 events were acquired from the samples.  
 











FL1 FITC CD90 488 525/20 BP 
FL3 Propidium iodide Viability 488 620/30 BP 
FL5 PE-Cy7 CD105 488 755 LP 
FL6 APC CD34 633 660/20 BP 
FL, fluorescent light; BP, band pass; LP, long pass 
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2.5.5 Analysis of flow cytometry data 
Data acquired was analysed using FlowJo v10.3 (FlowJo LLC, USA), a flow cytometry 
analysis software. Compensation controls were used to set up the compensation matrix and 
applied to all samples prior to gating.  
To determine the boundary between positive and negative samples, a negative gating control 
was used. FMO controls are stained for all fluorophores except for one fluorophore hence can 
be used to demarcate negative populations. Unstained (US) samples were not used as a 
negative gating control due to poor alignment with FMO controls, especially in the CD105 
PE-Cy7 (FL5) channel (Figure 2-4). 
 
 
Figure 2-4: Representative bivariate dot plot comparing gates set using FMO controls and 
unstained samples. 
FMO controls were used as the negative gating control due to better representation of the 
negative population. The gate set using the unstained sample has a lower threshold compared 
to the gate set by the FMO control for the CD105 PE-Cy7 channel. 
 
CPCs were gated for size, single cells by excluding doublet populations, live cells and the 
expression of cell markers (Figure 2-5). Cells were gated for size by plotting FSC-area vs. 
SSC-area. Doublet populations were then excluded using FSC-area vs. FSC-height. Using the 
negative controls, gates were set for viability (viability PI, FL3 channel), CD34 (CD34 APC, 
FL6 channel), CD90 (CD90 FITC, FL1channel) and, CD105 (CD105 PE-Cy7, FL5 channel). 
The gates set using the negative gating control were then applied to the FS samples. 













from analysis as they non-specifically bind antibodies which can give false positive results. 
CD34- cells were then gated from the live cell population to exclude the population of 




Figure 2-5: Gating protocol for CPCs. 
CPCs were first gated for size; doublet populations were then excluded; and live cells were 
gated prior to analysing the expression of cell markers. RAA CPCs shown in the figure. 
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Gating for cell viability (live/dead cells)
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2.6 Exposure of serum deprived cardiac progenitor cells to normoxic and hypoxic 
conditions 
RAA CPCs and LV CPCs were either seeded alone or in combination onto T25 flasks at a 
seeding density of 4,000 cells/cm2. To mimic the ischaemic environments as in IHD, cells 
were cultured in serum deprivation in hypoxic conditions (Table 2-5). Normoxic conditions 
were used as a control. 
 
Table 2-5: Table showing cell number used for serum-free treatment in normoxia and hypoxia. 
Culture 
conditions 
Cell groups Number of cells/T25 flask 
Normoxia 
(20% O2) 
RAA CPC 100,000 cells 
LV CPC 100,000 cells 
RAA and LV CPC 
(Combination) 
50,000 RAA CPC +  
50,000 LV CPC 
Hypoxia 
(1% O2) 
RAA CPC 100,000 cells 
LV CPC 100,000 cells 
RAA and LV CPC 
(Combination) 
50,000 RAA CPC +  
50,000 LV CPC 
 
Cells were cultured in a 5% CO2/95% air humidified incubator at 37°C for 24 hours to allow 
cells to adhere. Following 24 hours, the culture media was changed to serum-free (SF) Ham’s 
F12 media containing Ham’s F12 nutrient mixture supplemented with 1X anti-anti. Cells in 
the normoxia group were cultured in 20% O2/5% CO2 humidified incubator for 72 hours 
while cells in the hypoxia group were cultured in 1% O2/5% CO2 humidified incubator for 72 
hours. 
2.6.1 Collection of conditioned media 
Following the experimental period, culture media was collected in a 15-mL tube and 
centrifuged at 300 RCF for 5 minutes. The cells were washed with PBS and the culture vessel 
was kept on ice for later ribonucleic acid (RNA) extraction (see chapter 2.6.2). The 
supernatant (conditioned media, CM) was collected, without disturbing the cell pellet, and 
aliquoted into sterile tubes. The CM was stored in a -80°C freezer for further experiments. 
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2.6.2 Collection of lysate for RNA extraction 
Following the collection of the CM, RNA was extracted from the cells. 700 μL of TRIzol 
lysis reagent (Invitrogen, USA) was added to the cells and rocked gently to cover the vessel 
surface. Cells were then disrupted and homogenised. The lysate was transferred to a 
microcentrifuge tube and stored in a -80°C freezer until RNA isolation (see chapter 2.7.1). 
 
2.7 Gene expression analysis in cardiac progenitor cells 
The mRNA expression of HIF1A, AKT1, FGF2 and PDGFA which encode for the proteins 
HIF-1α, AKT1, bFGF and PDGF-A respectively. HIF-1α and AKT1 are involved in cell 
signalling pathways in cardioprotection, angiogenesis and differentiation. bFGF and PDGF-A 
are secreted by CPCs to mediate their therapeutic effects for cardiac repair.(7) 
2.7.1 RNA isolation 
RNA was extracted from the lysate prepared after CPCs were subjected to serum deprived 
conditions in normoxia and hypoxia (see chapter 2.6.2) according to the established protocol 
in the Katare laboratory. RNA extraction was performed in a fume hood. 
The lysates were thawed and incubated at room temperature to allow complete dissociation of 
the nucleoproteins complex. Thereafter, 140 µL of chloroform was added to the samples. The 
samples were mixed and incubated at room temperature for 3 minutes. Samples were 
centrifuged at 12,000 RCF for 15 minutes at 4°C for phase separation. After centrifugation, 
the mixture separates into an upper colourless aqueous phase, middle interphase and lower red 
phenol-chloroform phase. The upper aqueous phase containing RNA is transferred to a new 
microcentrifuge tube, taking care not to disturb other layers.  
RNA in the aqueous phase was then precipitated by addition of 350 µL of isopropanol and 
incubating at room temperature for 10 minutes. The sample was then centrifuged at 12,000 
RCF for 10 minutes at 4°C. The resulting RNA pellet was washed twice with 700 µL of 75% 
ethanol. Following a brief vortex, the RNA containing tube was centrifuged at 7,500 RCF for 
5 minutes at 4°C. The supernatant was removed, and the resulting RNA pellet was air dried 
for 10 to 30 minutes, taking care not to fully dry the pellet. Once the RNA pellet was dried, 25 
µL RNase-free water was added, the tube tapped to resuspend the pellet. The tube was briefly 
centrifuged then incubated on a heat block set at 55-60°C for 15 minutes to allow the pellet to 
completely dissolve.  
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RNA concentration and A260/A280 (≥1.8) were measured by loading 2 µL of the RNA 
solution onto a MaestroNano spectrophotometer (Maestrogen, Taiwan). The RNA sample was 
then stored at -80°C. 
2.7.2 Reverse transcription 
RNA samples were thawed on ice. RNA concentration was measured and diluted to a 
concentration of 100 ng/µL in nuclease free water. Recombinant DNase (rDNase) (Macherey-
Nagel, Germany) was added to 20 µL of the diluted RNA sample. The sample was then 
incubated at room temperature for 15 minutes. Following incubation, rDNase was heat 
inactivated by incubating the samples on a heat block set at 75°C for 10 minutes. RNA 
concentration was measured following DNase treatment. 
The reverse transcription (RT) was performed to synthesise cDNA using Primescript RT 
reagent kit (Takara, Japan) according to the manufacturer’s protocol. RNA was added to the 
RT master mix consisting of primescript buffer, primescript enzyme mix, oligo dT primer, 
random hexamers and nuclease free water in 8 strip tubes (Table 2-6). Nuclease free water 
was added to the RT master mix as a no reverse transcriptase control (NRT). Tubes were then 
loaded into a thermal cycler, incubated at 37°C for 15 minutes and then heated to 85°C for 5 
seconds to heat inactivate the reverse transcriptase. Samples were cooled to 4 °C and stored at 
-20°C overnight. 
 
Table 2-6: Final concentration and volume of reagents used for the RT mix for reverse 
transcription. 
Reagents Final concentration Volume/reaction 
PrimeScript buffer (5X) 1X 2 µL 
PrimeScript enzyme mix  0.5 µL 
Oligo dT primer (50 µM) 25 pmol 0.5 µL 
Random 6 mers (100 µM) 50 pmol 0.5 µL 
Total RNA 250 ng/10 µL 250 ng 
Nuclease free water  Variable 
Total volume  10 µL 
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2.7.3 Real time polymerase chain reaction 
The following day, the synthesised cDNA was diluted 1:1 in nuclease-free water. The 
polymerase chain reaction (PCR) master mix (Takara, Japan) was then prepared according to 
the manufacturer’s protocol (Table 2-7). PCR primers (Sigma-Aldrich, USA) were 
reconstituted in Tris-EDTA (TE) buffer. PCR primers have been tested and validated by the 
manufacturer. 18S was used as a reference gene and was added for every plate used. 
 





SYBR Premix Ex Taq (2X) 1X 5 µL 
PCR forward primer (10 µM) 0.2 µM 0.2 µL 
PCR reverse primer (10 µM) 0.2 µM 0.2 µL 
Nuclease free water  2.6 µL 
Diluted cDNA  2 µL 
Total  10 µL 
 
Two microlitres of diluted cDNA was aliquoted into a 96 well PCR plate (triplicate/gene). For 
the negative controls, NRT was aliquoted and nuclease free water was aliquoted as a no 
template control (NTC). Thereafter, 8 μL of PCR master mix was aliquoted into each well. 
The plate was then vortexed briefly and loaded onto a PCR thermal cycler. The initial 
denaturation step was set at 95°C for 30 seconds. Following denaturation, PCR was 
performed at 95°C for 5 seconds and 60°C for 30 seconds for 40 cycles. The cycle threshold 
(CT) values were determined using the Step One plus system software.  
The fold changes in mRNA expression was calculated manually relative to the RAA 
normoxia group using the 2-ΔΔCT method.(141) ΔCT was calculated by subtracting the mean 
CT of the reference gene (18S) from each of the mean CT values of the target genes of 
interest. ΔΔCT was then calculated relative to the RAA normoxia group by subtracting the 
ΔCT value of RAA normoxia from all the other CPC groups within the gene of interest. 
Finally, the fold changes in gene expression were calculated by exponentiation of 2 to the -
ΔΔCT (2-ΔΔCT).  
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2.8 Enzyme-linked immunosorbent assay (ELISA) for quantification of growth 
factors in CM 
IGF-1 and VEGF-A in the CM were quantified using a commercially available ELISA kit 
(Elisakit.com, Australia) according to the manufacturer’s protocol. Each ELISA kit contains a 
strip well plate pre-coated with capture antibody, lyophilised protein standard, wash buffer, 
biotin-labelled detection antibody, streptavidin-horseradish peroxidase (HRP) conjugate, 
tetramethylbenzidine (TMB) substrate and stop solution. 
IGF-1 and VEGF-A are important paracrine factors secreted by stem cells which exert 
cardioprotective and angiogenic effects respectively.(7) 
Lower limit of quantification (LLQ) for both assays were <5 pg/mL (determined by adding 3 
standard deviations to the mean optical density (OD) of 5 zero antigen replicates). 
2.8.1 Measurement of IGF-1 and VEGF-A 
The CM stored in the -80°C freezer was thawed on ice prior to performing the assay. 
IGF-1 protein standards were prepared in duplicates ranging from 5000 pg/mL to 78.125 
pg/mL in a 2-fold serial dilution in Ham’s F12 basal media. VEGF-A protein standards were 
prepared in duplicates ranging from 2000 pg/mL to 31.25 pg/mL in a 2-fold serial dilution in 
Ham’s F12 basal media.  
One hundred microlitres of the standards, zero standard (Ham’s F12 basal media) and CM 
were added to the pre-coated plates in duplicates, sealed and incubated at room temperature 
for 2 hours. Following incubation, well contents were discarded, and the plate washed 4 times 
with 250 µL wash buffer per well. Residual wash buffer was removed between each wash 
step by inverting and taping the plate on paper towels. One hundred microlitres of biotin-
labelled detection antibody (200 ng/mL) was added to each well. The plate was sealed and 
incubated at room temperature for 1 hour. The well contents were then discarded and washed 
as above. Next, 100 µL of freshly diluted streptavidin-HRP conjugate (500-fold dilution) was 
added to each well. The plate was then sealed and incubated for 45 minutes. Following 
incubation, the wells were washed 5 times with wash buffer.  
Subsequent steps were performed protected from light. After washing, 100 µL of TMB 
substrate was added to each well and incubated in the dark for approximately 15 minutes. The 
development process of the plate (blue colour) was checked every 5 minutes to prevent over 
development of the plate. To reaction was stopped by the addition of 50 µL of the stop 
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solution to each well resulting in a colour change from blue to yellow. Finally, 
OD/absorbance of the plate was measured using a microplate reader set at 450 nm. 
For calculation of the results, first the mean of the zero standards was subtracted from the 
standards and samples. Using GraphPad Prism 7, a standard curve was generated by plotting 
OD on the y-axis versus log of the standard concentrations on the x-axis. Standard 
concentrations were converted to base 10 logarithm (Log). A 4-parameter logistic curve was 
fitted to the standards (R2 >0.99). The Log(Concentration) of the samples were then 
interpolated from the standard curve. The concentration of the samples was then calculated by 
exponentiation of 10 to the Log(Concentration) (10Log(Concentration)). 
 
2.9 Effect of CM on apoptosis in cardiomyocytes cultured under hypoxic conditions 
The effects of the CM on apoptosis of AC16 cardiomyocytes treated under hypoxic condition 
was measured using a Caspase-Glo 3/7 assay as previously described.(8) Caspases are a group 
of proteases which play an important role in various cellular processes involving programmed 
cell death and inflammation. Caspase -3 and -7 are known as executioner caspases which 
execute the cellular responses leading to apoptosis. 
2.9.1 Caspase-Glo 3/7 and CyQUANT proliferation multiplexed assay 
Caspase-Glo 3/7 assay (Promega, USA) was used to quantify caspase -3/-7 activity following 
culture of AC16 cardiomyocytes in hypoxia for 72 hours. The assay contains a luminogenic 
substrate with the tetrapeptide sequence DEVD (Asp-Glu-Val-Asp). DEVD is cleaved by 
caspase 3/7 and aminoluciferin, a substrate for luciferase is released. This allows for the 
luciferase reaction to occur resulting in the production of light/luminescence. 
Basal caspase 3/7 are expressed in cells under normal culture conditions and is proportional to 
cell number. Therefore, caspase activity was normalised to cell number by multiplexing the 
caspase assay with a CyQUANT cell proliferation assay (Invitrogen, USA). 
For this assay, AC16 cardiomyocytes were seeded onto a 96-well plate at 3,000 cells/well in 
triplicates and supplemented with 100 L DMEM/F12 complete media and cultured for 24 
hours. After confirming that the cells were attached to the surface, culture media was replaced 
with new media consisting of 50 μL of CM and 50 μL of SF Ham’s F12. Negative control 
wells were supplemented with 100 μL SF Ham’s F12. Cells were then incubated in hypoxia 
(1% O2) for 72 hours. 
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At the end of the experimental period, culture media was removed and 25 μL of PBS was 
added. Next, 25 μL of caspase reagent (reconstituted according to the manufacturers’ 
protocol) was added to each well. In addition, 25 μL PBS and 25 μL caspase reagent were 
added to empty wells to be used as blank measurements. Contents of the well were gently 
mixed on a plate shaker set at 250 RPM for 1 minute. The plate was then incubated at room 
temperature for 30 to 60 minutes. Following incubation, luminescence was measured using a 
plate reader. 
Following the caspase assay, CyQUANT reagent was prepared at a concentration of 2X and 
50 μL was added to each well for a final concentration of 1X. The plate was then incubated at 
room temperature in the dark for 10 minutes. Following incubation, the fluorescence was 
measured using a plate reader set at excitation at 480 nm and emission at 520 nm. 
Caspase activity (relative luminescent units, RLU) was then normalised to cell number 
(relative fluorescence units, RFU) (caspase activity/cell number) prior to analysis.  
 
2.10 HIF-1α protein expression in AC16 cardiomyocytes exposed to hypoxia 
following treatment with CM 
2.10.1 Protein extraction from AC16 cardiomyocytes 
AC16 cardiomyocytes were plated onto 6-well plates at 5x105 cells/well in triplicates in 1000 
µL DMEM/F12 complete media and cultured for 24 hours. After confirming that the cells 
were attached to the surface, culture media was replaced with new media consisting of 500 μL 
of CM and 500 μL of SF Ham’s F12. Negative control wells were supplemented with 1000 
μL SF Ham’s F12. Cells were then exposed to hypoxia (1% O2) for 72 hours. 
At the end of the experimental period, protein was extracted from the cells using a cell 
extraction buffer PTR (HIF1a Human SimpleStep ELISA kit, Abcam, UK) according to the 
manufacturer’s protocol. In brief, culture media was removed, and the cells were washed 
twice with ice-cold PBS. Cells were then homogenised with 100 μL of ice-cold cell lysis 
buffer and the lysate was collected and incubated on ice for 15 minutes. The lysate was then 
centrifuged at 18,000 RCF for 20 minutes at 4°C. The supernatant was transferred to fresh 
tubes and the pellet discarded. Samples were stored at -80°C until further analysis. 
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2.10.2 Measuring of protein concentration using Bradford assay 
On the day of the ELISA, protein samples were thawed and kept on ice. Protein standards 
were prepared using bovine serum albumin (BSA) ranging from 1.25 to 25 μg/mL diluted 
with the Bradford reagent (Bio-Rad, USA). Bradford reagent was used as a blank. Each 
sample was diluted in Bradford reagent (400-fold dilution). Standards and samples were then 
briefly mixed by inversion. Next, 100 μL of the standards, blanks and samples were then 
added to a microplate in triplicates. Absorbance/OD was read using a microplate reader at 595 
nm.  
The mean of the zero standards was subtracted from the standards and samples. Using 
GraphPad Prism 7, a standard curve was generated by plotting OD on the y-axis versus 
standard concentrations on the x-axis. A linear regression was fitted to the standards (R 
>0.99). The sample concentrations were interpolated from the linear regression. The 
concentrations were then corrected for the dilution factor. The samples were then diluted to a 
concentration of 200 μg/mL in cell extraction buffer PTR. 
2.10.3 Enzyme linked immunosorbent assay of HIF-1α alpha extracted from AC16 
cardiomyocytes 
HIF-1α was measured using HIF1a Human SimpleStep ELISA kit (Abcam, UK) according to 
the manufacturer’s protocol. 
Standards were prepared from 15 ng/mL to 0.23 ng/mL in a 2-fold serial dilution. Cell 
extraction buffer was used as a blank. Fifty microlitres of standards, blanks and samples were 
added to the wells of the ELISA plate in duplicates. Fifty microlitres of antibody solution was 
then added to each of the wells. The plate was sealed and incubated in a plate shaker set at 
400 RPM at room temperature for 1 hour. Following incubation, the well contents were 
discarded. Wells were washed three times with 350 μL wash buffer PT. Residual wash buffer 
was removed between each wash step and after the last wash step by inverting and tapping the 
plate on paper towels.  
Subsequent steps were performed protected from light. One hundred microliters of TMB 
substrate was added to each well and incubated on a plate shaker set at 400 RPM at room 
temperature for 10 minutes. To stop the reaction, 100 µL of the stop solution was added to 
each well resulting in a colour change from blue to yellow. Optical density (OD)/absorbance 
of the plate was measured using a microplate reader set at 450 nm.  
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Concentration was calculated as previously explained (see chapter 2.8.1). Sample 
concentrations were then corrected to ng/mL/100 μg of protein. 
 
2.11 Angiogenic effects of CM on HUVECs using a tube formation assay 
The angiogenic potential of the CM were measured in HUVECs using a tube formation assay. 
HUVECs migrate and differentiate to form capillary-like structures which indicates the 
level/efficacy of angiogenesis following the treatment of interest. 
Prior to the assay, matrigel matrix (Corning, USA) and CM were thawed overnight at 4°C. At 
least 40 minutes prior to the assay, 50 µL of matrigel matrix was added to wells of a 96-well 
plate. Both the 96-well plate and pipette tips were cooled to 4°C to prevent gelling of the 
matrix. Caution was taken not to introduce bubbles when adding matrix to the wells as this 
may disrupt the tube formation. The plate was then incubated at room temperature for 10 
minutes and then incubated at 37°C for 30-60 minutes. 
HUVECs were resuspended in 1 mL SF EBM-2 media containing EBM-2 basal media (Lonza, 
USA) supplemented with 1X anti-anti (Gibco, USA) and counted using a haemocytometer. 
HUVECs were then seeded onto the matrigel-coated wells in triplicates (18,000 cells per well 
in 50 μL of SF EBM-2). Thereafter, 50 μL of CM was added to the treatment wells. For the 
negative control, an additional 50 μL of SF EBM-2 was added. For the positive control, 
HUVECs in 100 μL EGM-2 complete media were seeded in triplicates (18,000 cells per well). 
The plate was then incubated in a 5% CO2/95% air humidified incubator at 37°C for 12 hours. 
At the end of the experimental period, phase contrast images at 4X magnification were taken 
using a microscope (Olympus, Japan) fitted with a microscope camera (Lumenera, USA). 
Images were then analysed using the software Fiji using the angiogenesis analyser plugin to 
quantify total tube length.(142) 
 
2.12 Statistical analysis 
Differences in cell marker expression between RAA CPCs and LV CPCs were compared 
using paired t-tests. 
IGF-1 and VEGF-A concentrations were normalised to a control group (RAA normoxic CM) 
to account for interpatient variability and allow comparison of the fold changes between the 
different groups in the same patient. The normalised data was log distributed. Hence, 
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statistical analysis was performed on the log10-transformed data. Two-way analysis of 
variance (ANOVA) was used for statistical analysis, followed by a Tukey post-hoc test. 
Gene expression data were normalised to RAA normoxia. Two-way ANOVA using log10-
transformed data was used to compare between the different groups, followed by a Turkey’s 
post hoc test. 
Caspase/CyQUANT data was normalised to the SF Ham’s F12 (SF F12) group. One-way 
ANOVA was performed on the log10-transformed data to compare the CM-treated groups 
against the control SF F12, followed by Dunnett’s post hoc test. Differences between the CM-
treated groups were compared using two-way ANOVA, followed by a Turkey’s post hoc test. 
Differences in HIF-1α protein expression in the CM-treated groups were compared against 
the negative control SF F12 using one-way ANOVA followed by a Dunnett’s post hoc test. 
Differences between CM-treated groups were compared using two-way ANOVA followed by 
a Turkey’s post hoc test.  
Differences in the total tube length from the tube formation assay of the CM-treated groups 
were compared against the negative control SF EBM-2 and positive control EGM-2 complete 
(EGM-2 COM) using one-way ANOVA followed by a Dunnett’s post hoc test. Differences 
between CM-treated groups were compared using two-way ANOVA followed by a Turkey’s 
post hoc test.  
Data represented as mean ± standard error of mean (SEM). Differences with a p-value ≤0.05 





3.1 Patient characteristics 
The medical history and echocardiographic reports were collected from all patients prior to 
surgery (Table 3-1). Information such as age, sex, medical history and echocardiogram report 
were available for each patient. All parameters were comparable across all the patients, except 
one patient had a reduced ejection fraction (<50 %) (patient number 237). 
 
Table 3-1: Table showing the characteristics from patients where heart tissue was collected 
and used to isolate CPCs. 
Patient 
number 
Age Sex BMI Diabetes Hypertension 
Ejection 
fraction (%) 
237 61 M 30.9 N Y 44 
421 65 M 28.9 N Y 58.5 
436 62 M 27.1 N Y 53 
493 64 F 26.4 N Y >60 
550 64 M 23.7 N N 50.5 
552 57 M 22.4 N N >60 
BMI, body mass index. 
 
3.2 Comparable expression of cell surface markers between RAA CPCs and LV 
CPCs 
CPCs were characterised for the expression of CD34, CD90 and CD105. The expression of 
cell markers was comparable between RAA CPCs and LV CPCs and there were no statistical 
differences. 
Majority of the cells were negative for CD34 population, although due the ischaemic nature 
of the tissue collected they still expressed CD34 positivity which was especially more in LV 
CPCs (80.9 ± 5.2% in RAA CPCs vs. 72.4 ± 8.3% in LV CPCs, p=0.298, n=4 patients, Figure 
3-1 A and C). This suggests that there are cells that express CD34 within the CPC population, 
most likely due to their heterogeneity. 
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CD34 negative population were then used to measure the expression of MSC markers, CD90 
and CD105. CD90 expression was higher in RAA CPCs compared to LV CPCs, but this was 
not statistically significant (72.4 ± 7.1% in RAA CPCs vs. 48.5 ± 17.0% in LV CPCs, 
p=0.277, n=4 patients, Figure 3-1 B and C). Interestingly, a previous study from our 
laboratory showed increased expression of CD90 in RAA CPCs.(8) The difference in the 
current study is possibly due to the smaller sample size due to limited time available for this 
project. CD105 expression was high in both RAA CPCs and LV CPCs, with nearly all cells 
expressing the cell marker (99.6 ± 0.12% in RAA CPCs vs. 99.5 ± 0.08% in LV CPCs, 
p=0.277, n=4 patients, Figure 3-1 B and C). Due to the high expression of CD105, the 
CD90+CD105+ cells were almost entirely dependent on CD90 expression (72.2 ± 7.1% in 




Figure 3-1: Immunophenotype of RAA CPCs and LV CPCs. 
A. Representative histograms showing the expression of CD34 (negative control, RAA CPC 
and LV CPC from left to right). B. Representative bivariate dot plots showing the expression 
of CD90 (y axis) and CD105 (x axis) within the CD34- population (negative control, RAA 
CPC and LV CPC from left to right). C. Quantitative bar graph showing the expression of 
CD34 negative population; CD90+, CD105+ and CD90+CD105+ populations (given CD34-) 
of RAA CPCs and LV CPCs (n=4 patients). Data represented as mean ± SEM %. Differences 
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3.3 Gene expression following serum deprivation in normoxia and hypoxia 
The mRNA expression of HIF1A, AKT1, FGF2 and PDGFA were measured following serum 
deprivation of CPCs cultured in normoxia and hypoxia. 
3.3.1 Decreased HIF1A mRNA expression in hypoxia 
Exposure of CPCs to hypoxia reduced the expression of HIF1A although the only significant 
difference was observed in the RAA+LV CPCs cultured in hypoxia when compared to RAA 
normoxia, LV normoxia and RAA + LV normoxia (0.42 ± 0.17 –fold in RAA + LV hypoxia; 
vs. 1.0 ± 0 –fold in RAA normoxia, p =0.0357; vs. 1.1 ± 0.17 –fold in LV normoxia, 
p=0.0272; vs. 1.15 ± 0.36 –fold in RAA + LV normoxia, p=0.0387; n=5 patients, Figure 3-2 
A). Other groups failed to exhibit any significant difference.  
Interestingly, comparison of HIF1A mRNA expression irrespective of the groups showed a 
significant reduction of HIF1A in hypoxia (normoxia vs. hypoxia, p=0.0002, n=5 patients, 3 
groups, Figure 3-2 B). 
3.3.2 Comparable AKT1, FGF2 and PDGFA mRNA expression in CPCs 
There were no statistically significant differences in mRNA expression of AKT1, FGF2 and 




































































































































































































































































































































































A, C, D & E. Quantitative bar graphs showing mRNA expression of CPCs of HIF1A, AKT1, 
FGF2 and PDGFA, respectively (n=5 patients, triplicates). Data represented as fold change ± 
SEM relative to RAA normoxia. Differences were compared using two-way ANOVA 
followed by a Turkey’s post hoc test; where * p≤0.05 vs. RAA normoxia; # p≤0.05 vs. LV 
normoxia; $ p≤0.05 vs. RAA + LV normoxia. B. Quantitative bar graph showing mRNA 
expression of HIF1A in CPCs cultured in normoxia vs. hypoxia (n=3 groups, triplicates). Data 
represented as fold change ± SEM relative to RAA normoxia. Differences were compared 
using two-way ANOVA; where *** p≤0.001 vs. normoxia group. 
 
3.4 IGF-1 and VEGF-A concentration in CM 
IGF-1 and VEGF-A concentration was measured in CM collected following culture of CPCs 
in normoxic and hypoxic conditions, cultured either alone or in combination, using ELISA.  
3.4.1 Comparable secretion of IGF-1 among CM from CPCs 
There were no significant differences in the IGF-1 concentration between the different CM. 
(Figure 3-3 A).  
Comparison of IGF-1 concentration irrespective of the groups showed a trend towards 
reduced IGF-1 concentration in hypoxic CM, although this was not significant (normoxic CM 
vs. hypoxic CM, p=0.0569, n=6 patients, 3 groups, Figure 3-3 B). 
3.4.2 Increased secretion of VEGF-A in hypoxia 
VEGF-A secretion was significantly upregulated in the hypoxic CM from RAA CPCs 
cultured in hypoxia (1.0 ± 0 -fold in RAA normoxia vs. 2.637 ± 0.405 -fold in RAA hypoxia, 
p=0.0412, n=6 patients). VEGF-A concentration was the highest in the CM combination 
group (RAA + LV) cultured in hypoxia which was significantly upregulated compared to both 
the RAA normoxia and RAA + LV normoxia groups (3.428 ± 0.787 –fold in RAA + LV 
hypoxia; vs. 1.0 ± 0 -fold in RAA normoxia, p=0.0084; vs. 1.241 ± 0.233 –fold in RAA + LV 
normoxia, p=0.0235; n=6 patients, Figure 3-3 C). VEGF-A concentration in CM was 
significantly increased in hypoxia groups compared to the normoxia groups (normoxic CM vs. 




Figure 3-3: IGF-1 and VEGF-A concentration in CM following serum deprivation of CPCs in 
normoxic and hypoxic conditions. 
A and C. Quantitative bar graphs showing IGF-1 and VEGF-A concentration in CM, 
respectively (n=6 patients, duplicates). Data represented as fold change ± SEM relative to 
RAA normoxic CM. Differences were compared using two-way ANOVA followed by a 
Turkey’s post hoc test; where * p≤0.05, ** p≤0.01 vs. RAA normoxic CM; # p≤0.05 vs. RAA 
+ LV normoxic CM. B and D. Quantitative bar graphs showing IGF-1 and VEGF-A 
concentration in CM, respectively, in normoxic CM and hypoxic CM (n=3 groups, duplicates). 
Differences were compared using two-way ANOVA; where **** p≤0.001 vs. normoxic CM. 
 
3.5 Anti-apoptotic effects of CM on serum deprived AC16 cardiomyocytes cultured 
under hypoxia 
CM collected from all CPC groups reduced apoptosis in AC16 cardiomyocytes compared to 





























































































































































































































































































normoxic CM, p=0.0001; RAA hypoxic CM, p=0.021; LV hypoxic CM, p=0.0005; RAA + 
LV hypoxic CM, p=0.0001; vs. SF F12 group, n=6 patients, Figure 3-4). 




Figure 3-4: Anti-apoptotic effects of CM on serum deprived AC16 cardiomyocytes cultured 
in hypoxic conditions. 
Quantitative bar graph showing caspase 3/7 activity of AC16 cardiomyocytes normalised to 
cell number (n=6 patients, triplicates). Data represented as fold change ± SEM in caspase 3/7 
activity relative to SF F12 group for each individual experiment performed (3 individual 
experiments performed, n=2 patients/experiment). Differences between CM-treated groups 
were compared against the control SF F12 group using one-way ANOVA followed by a 
Dunnett’s post hoc test; where * p≤0.05, ** p≤0.01, *** p≤0.001, *** p≤0.0001 vs. SF F12. 
Differences among CM-treated groups were compared using two-way ANOVA, followed by 
a Turkey’s post hoc test. 
 
3.6 Normoxic CM from combination of CPCs stimulates HIF-1α protein expression 
in AC16 cardiomyocytes cultured in hypoxic conditions 
All CM-treated groups had a trend to stimulate HIF-1α in AC16 cardiomyocytes following 
culture in hypoxic conditions, while only the RAA + LV normoxic CM showed a statistically 
significant increase in HIF-1α protein concentration compared to the SF F12 group (0.18 ± 
0.02 ng/mL/100 μg protein in RAA + LV normoxic CM vs. 0.11 ± 0.008 ng/mL/100 μg 
protein in SF F12 group, p=0.0177, n=5 patients, Figure 3-5). 





Figure 3-5: Effect of CM to stimulate HIF-1α protein expression in serum deprived AC16 
cardiomyocytes cultured in hypoxic conditions. 
Quantitative bar graph showing HIF-1α protein concentration (n=5 patients, duplicates). Data 
represented as ng/mL/100 μg of protein ± SEM. Differences between CM-treated groups were 
compared against the control SF F12 group using one-way ANOVA followed by a Dunnett’s 
post hoc test; where * p≤0.05 vs. SF F12. Differences among CM-treated groups were 
compared using two-way ANOVA, followed by a Turkey’s post hoc test. 
 
3.7 Angiogenic effects of CM on tube formation in HUVECs 
The effect of CM to improve the angiogenic potential of endothelial cells was estimated by 
measuring the tube forming ability of HUVECs. All CM-treated groups showed a significant 
improvement in angiogenesis compared to the negative control SF EBM-2 group. Importantly, 
this improvement was comparable to the positive control EGM-2 complete group in only the 
LV hypoxic CM and RAA + LV hypoxic CM (Figure 3-6 B). 
Cells treated with CM collected from the RAA + LV CPCs exposed to hypoxia showed a 
significant increase in angiogenesis compared to the cells treated with CM collected from LV 
CPCs exposed to normoxia suggesting that RAA + LV hypoxic CM contained the highest 
levels of angiogenic factors (20713 ± 748.4 μm/field in RAA + LV hypoxic CM vs. 15193 ± 
394.4 μm/field in LV normoxic CM, p=0.0326, n=3 patients, Figure 3-6 B).  
Comparison of angiogenic effects of normoxic and hypoxic CM irrespective of the groups 
showed a significant increase in tube formation by hypoxic CM (normoxic CM vs. hypoxic 




Figure 3-6: Angiogenic effects of CM on tube formation using HUVECs. 
A. Phase contrast images showing tube formation in HUVECs taken at 4X magnification 12 
hours after initial seeding. Scale bars, 400 µm B. Quantitative bar graph showing the total 
tube length (n=3 patients, triplicates). Data represented as mean ± SEM μm/field. Differences 
between CM-treated groups were compared against the controls using one-way ANOVA 
followed by a Dunnett’s post hoc test; where * p≤0.05; ** p≤0.01; **** p≤0.0001 vs. SF 
EBM-2; # p≤0.05; ## p≤0.01; ### p≤0.001; vs. EGM-2 COM. Differences among CM-treated 
groups were compared using two-way ANOVA followed by a Turkey’s post hoc test; where 
$ p≤0.05 vs. LV normoxic CM. C. Quantitative bar graph showing total tube length of 
normoxic CM and hypoxic CM (n=3 groups, triplicates). Differences were compared using 
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4.1 Summary of results 
There were no significant differences in the expression of cell markers between RAA CPCs 
and LV CPCs (Table 4-1). CD34 expression in CPCs was higher than anticipated. 
The following outlines the results from serum deprivation of CPCs cultured under normoxia 
and hypoxia (Table 4-2). There were no statistically significant differences in the gene 
expression of AKT1, FGF2 and PDGFA when CPCs were cultured under normoxia and 
hypoxia. Interestingly, HIF1A gene expression was only significantly down-regulated in the 
combination group cultured in hypoxia and in hypoxia irrespective of groups. Secretion of 
IGF-1 into CM was comparable among all CPC groups, although there was a decreased trend 
in hypoxia. However, secretion of VEGF-A was significantly increased by LV CPCs cultured 
in hypoxia and combination group cultured in hypoxia. 
The following outlines the results from functional paracrine effects of CPCs, which were 
evaluated using the CM collected from serum deprivation of CPCs cultured in normoxia and 
hypoxia (Table 4-3). Apoptosis was significantly decreased in AC16 cardiomyocytes exposed 
to serum deprivation and hypoxia when treated with CM from all CPCs groups (normoxic 
CM and hypoxic CM). HIF-1α protein was only significantly upregulated when treated with 
RAA + LV normoxic CM, which suggests that the paracrine profile from the combination in 
normoxia could stimulate HIF-1α.  
Angiogenic potential of CM from CPCs as assessed by tube formation using HUVECs, 
significantly increased when treated with CM from all CPC groups except LV normoxic CM, 
compared to the negative control where cells were treated with SF EBM-2 media alone. 
Interestingly, the level of tube formation in HUVECs treated with hypoxic CM from LV 
CPCs and RAA + LV CPC group were as comparable to the positive control where cells were 
treated with EGM-2 complete media. RAA + LV hypoxic CM showed the highest 
angiogenesis which was the only group significantly increased compared to LV normoxic CM. 
Together, these results suggest that combination of RAA CPCs and LV CPCs demonstrate 
better effects on the therapeutic mechanisms of cardiac repair through synergistic or 
complimentary paracrine effects compared to single cultures. 
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Table 4-1: Overview of differences in cell markers between RAA CPCs and LV CPCs. 
Cell marker RAA CPC LV CPC 
CD34- - - 
CD90+ - - 
CD105+ - - 
CD90+CD105+ - - 
- indicates no significant difference. 
 
Table 4-2: Overview of differences in gene expression from serum deprivation of CPCs under 









HIF1A - - - ↓ ↓ ↓↓ 
Normoxia vs. hypoxia - ↓ 
AKT1 - - - - - - 
FGF2 - - - - - - 
PDGFA - - - - - - 
- indicates no significant difference; ↓ and ↓↓ indicates degrees of relative differences. 
 
Table 4-3: Overview of differences in functional paracrine effects of CM from CPCs. 
Paracrine effects 







IGF-1 concentration in CM - - - - - - 
VEGF-A concentration in CM - ↑ - ↑↑ ↑ ↑↑↑ 
Normoxic CM vs. hypoxic CM - ↑ 
Anti-apoptotic effects ↑ ↑ ↑ ↑ ↑ ↑ 
Stimulation/upregulation of HIF-1α - - ↑ - - - 
Angiogenesis ↑↑ ↑ ↑↑ ↑↑ ↑↑↑ ↑↑↑↑ 
Normoxic CM vs. hypoxic CM - ↑ 




4.2 Discussion of results 
4.2.1 CD34 expression in CPCs 
Previously CD34 was thought to be a specific marker for haematopoietic cells although it is 
also expressed on non-haematopoietic cells.(140) However, CD34+ cells are also present in 
the heart as cardiac endothelial precursors, which in additions to CD34, also express the 
cardiac cell marker, homebox gene NKX2.5.(143,144) In this study both RAA CPCs and LV 
CPCs expressed CD34. Of note, CD34+ cells were present in CPCs isolated from the RAA 
and LV tissue contain a heterogeneous population of cells including cells from the epicardium. 
RAA tissue consisted of endocardial, myocardial and epicardial tissue whereas LV tissue 
consisted of mainly epicardial and myocardial tissue. Similarly, Messina et al. showed the 
presence of CD34+ cells in CDCs, which like the cells in this study, contain heterogeneous 
populations of CPCs.(88) Hence, although it was expected that only a minimal expression of 
CD34+ cells in CPCs from the RAA and LV, due to their heterogeneity presence of CD34+ 
cells are inevitable. 
In addition to the expression of CD34 in the heart, the CD34+ cells may be a result from 
residual adipose tissue and peripheral blood during CPC isolation from the cardiac tissue. 
Moreover following ischaemic injury to the heart, cells from the bone marrow (including 
CD34+ cells) are mobilised into the peripheral blood and it has been suggested that these cells 
may subsequently engraft into the heart.(145,146) 
4.2.2 HIF1A gene expression in hypoxia 
An unexpected finding in this study was the decreased HIF1A gene expression after exposing 
the CPCs to hypoxia, although only the combination group showed a significant decrease. 
Studies have shown significant increase in HIF1A expression following acute hypoxia (at 4 
hours), however, prolonged hypoxia (≥12 hours) showed a decrease in HIF1A 
expression.(147) Several mechanisms have been proposed for this decrease in HIF1A 
following prolonged hypoxia through negative feedback mechanisms to prevent excessive 
accumulation of HIF-1α. One such mechanism is the upregulation of antisense HIF-1α (aHIF-
1α) and miR-429 both of which are increased in hypoxia.(147,148) Further, tristetraprolin 
(TTP), a mRNA destabilising protein, is also implicated in HIF1A mRNA destabilisation 
following hypoxia.(149) While these factors were not measured in this project due to time 
constraints, it is possible that CPCs exposed to prolonged hypoxia also activate these factors 
to reduce HIF1A expression. 
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Interestingly, the decrease in HIF1A expression in the RAA + LV CPCs cultured in hypoxia 
contradicts the level of VEGF-A concentration which was highest in the CM collected from 
this group. VEGF-A is upregulated in hypoxia through the transcriptional action of HIF-1, 
which suggests that HIF-1 concentrations were highest in the combination group cultured in 
hypoxia. HIF-1α protein is heavily regulated post-translationally so no conclusions can be 
made solely on the mRNA expression.(130) Therefore, the expression of HIF-1α protein in 
the CPCs after exposing them to hypoxia needs to be measured to observe any definite 
differences between the groups. 
4.2.3 Paracrine factor secretion 
IGF-1 concentration was comparable across all CM, although there was a trend towards a 
decrease in hypoxia (P=0.0569). IGF-1 concentration in CM from MSCs is often increased in 
hypoxia.(109) In osteoblasts, IGF-1 expression was decreased in hypoxia.(150) This was due 
to the decrease in Runt-related transcription factor 2 (Runx2) in hypoxia, an osteoblast 
transcription factor which can activate an upstream response element in the IGF-I gene 
promoter. In vascular endothelial cells, IGF-1 expression was decreased in hypoxia through 
the actions of insulin-like growth factor binding protein (IGFBP), a group of carrier proteins 
for IGF-1 which modulate IGF-1 activity which can be both stimulatory or inhibitory.(151) 
Although these mechanisms are likely to be cell specific, c-Kit+ CSC/CPCs have been shown 
to differentiate into osteogenic and vascular lineages.(152) However, these results are not 
significant and conclusions about IGF-1 secretion by CPCs in hypoxia cannot be made based 
on current evidence. 
VEGF-A concentration was significantly increased in CM collected from CPCs and 
particularly in the RAA hypoxic CM and RAA + LV hypoxic CM. These results are 
consistent with literature which show an increase in VEGF-A concentration in hypoxia 
mediated by its increased transcription by HIF-1.(128) These results suggest that combination 
of RAA CPCs and LV CPCs have synergistic effects to increase VEGF-A concentration 
following exposure to hypoxia. 
4.2.4 Anti-apoptotic effects of CM on cardiomyocytes 
CM from all cell types decreased apoptosis in AC16 cardiomyocytes subjected to serum 
deprivation and hypoxia due to the paracrine stimulation of various pro-survival pathways. 
Previously, the anti-apoptotic effects of RAA hypoxic CM were mediated through the 
PI3K/AKT and PKCε pathways, while LV hypoxic CM mediated these effects through the 
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PKCε pathway.(8) Anti-apoptotic effects of RAA + LV hypoxic CM were likely mediated 
through both pathways which may synergise, however, its anti-apoptotic effects were 
comparable to both the RAA hypoxic CM and LV hypoxic CM. 
IGF-1 and VEGF-A both mediate their anti-apoptotic effects through the PI3K/AKT 
pathway.(7) VEGF-A concentration was significantly higher in RAA hypoxic CM and RAA 
+ LV hypoxic CM which suggests were mediated through the PI3K/AKT pathway. 
Quantification of paracrine factors in CM involved in the signaling of PKCε pathway such as 
EPO and bFGF may ascertain the anti-apoptotic effects of LV hypoxic CM and other CM.(7) 
Investigation of other pro-survival pathways may identify other mechanisms involved in the 
anti-apoptotic effects of CM, including the normoxic CM in which the mechanisms are 
currently unknown. 
4.2.5 Paracrine stimulation of HIF-1α through a hypoxia-independent pathway 
RAA + LV normoxic CM stimulated the expression of HIF-1α protein in cardiomyocytes 
cultured in hypoxia. Hypoxia-independent pathways including the PI3K/AKT and PKCε 
signalling have been shown to enhance the expression of HIF-1α.(131,132) As discussed 
previously, RAA CPCs and LV CPCs release paracrine factors which act through these 
pathways. The upregulation of HIF-1α was likely due to the RAA + LV normoxic CM 
containing paracrine factor able to stimulate the expression of HIF-1α through these various 
pathways. Further mechanistic studies may elude to the factors and pathways that are 
involved in stimulation of HIF-1α expression by RAA + LV normoxic CM. 
4.2.6 Angiogenic paracrine effects in combination cell therapy 
Combination of RAA and LV CPCs hypoxic CM showed the highest levels of angiogenesis. 
This was likely due to the synergistic or complimentary paracrine effects consisting of the 
highest levels of angiogenic paracrine factors.  
Angiogenesis is increased by VEGF-A, which was significantly increased in only the RAA 
hypoxic CM and the RAA + LV hypoxic CM. Angiogenesis was second highest in the LV 
hypoxic CM, although VEGF-A was not significantly increased in the CM. Therefore, 
increased angiogenesis in this group are likely to be explained by other angiogenic factors that 
are stimulated by hypoxia.(128) Hypoxic CM significantly increased angiogenesis in 
HUVECs. This is likely due to the increased secretion of angiogenic factors, especially VEGF, 
in hypoxia.(128) 
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Among the CM-treated groups, LV normoxic CM had the lowest tube formations, most likely 
due to the absence or low levels of angiogenic factors. Recently, a study showed that severe 
hypoxia can induce quiescence and reduce the vasculogenic potential of CPCs, through the 
decreased expression of c-MYC.(153) As the left ventricle is often subjected to greater 
ischaemic stresses compared to the right atrium, LV CPCs may be more senescent and have 
reduced functional effects on neovascularisation. This result may also be due to the small 
sample size (n=3), resulting in low statistical power and no conclusions can be made based on 
the current evidence. 
 
4.3 Strengths of the study 
As CPCs were isolated from the same patient, experiments could be performed by using 
patient-matched samples and at matched passages. This was advantageous to the study as the 
effects of patient-related factors and inter-patient variations in CPC function could be limited 
when comparing between the different CPC groups.  
CPCs are primary cells which are unable to replicate indefinitely reaching senescence in 
culture which can affect their phenotype and reparative potential.(154,155) Therefore, RAA 
CPCs and LV CPCs from each patient were paired for passages to prevent any differences in 
stem cell function due to differences in passage number. 
As this study employed an in vitro approach to assess the paracrine effects of CPCs, processes 
and mechanisms involved in cardiac repair could be analysed in isolation, whereas these 
processes would occur simultaneously in in vivo studies. Ascertaining mechanisms of the 
functional effects of processes involved in cardiac repair is important to understanding the 
therapeutic benefits of cell therapy.  
 
4.4 Limitations of the study 
4.4.1 Small sample size 
Due to constraints in time and resources, and technical difficulties with experiments, the 
sample size was low, especially for characterising CPCs using flow cytometry (n=4 patients) 
and measuring angiogenic effects of CM using a tube formation assay (n=3 patients) 
experiments. The low sample size reduces the power of this study and may have been 
insufficient to show significant differences between groups. 
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4.4.2 Inadequate characterisation of CPCs 
CPCs were isolated and characterised using collagenase II to release stromal cells containing 
CPCs from the cardiac tissue. These cells were then cultured and expanded as CPCs. There 
are several limitations in the methods used to characterise these cells.  
Cardiac tissue is composed of several cell types and tissue including cardiomyocytes, smooth 
muscle cells, endothelial cells, fibroblasts, adipose tissue, and a small population of stem cells. 
Therefore, the isolation of CPCs is possibly susceptible to contamination. Daily examination 
of cells was carried out to observe any signs of contamination or changes in cell morphology. 
Fibroblast contamination was the most concerning as these cells show a similar mesenchymal 
cell morphology to CPCs. This was previously examined in the Katare laboratory which 
showed that CPCs stained negative for the cardiac fibroblast marker, fibroblast surface 
protein 1.(8) Isolation of CPCs was executed using the established Katare laboratory protocol, 
which showed no fibroblast contamination, and utmost care was taken to eliminate the 
possibility of contamination in this study.  
4.4.3 Serum deprivation and hypoxia to model stimulated ischaemia 
The area of the infarct in IHD is characterised by hypoxia, decreased supply of nutrients 
(serum deprivation), acidosis, and inflammation. Stimulated ischaemia was simplified in this 
study and only serum deprivation and hypoxia were used to stimulate ischaemia in vitro, 
however, these conditions are sufficient to induce apoptosis and affect hypoxia-induced 
signalling which were crucial aspects to this study.(156–159) 
Furthermore, physiological oxygen levels in the microenvironment of stem cells, which range 
from 1-5%, should be used to assess stem cell function to better approximate in vivo 
conditions, rather than the normal culture conditions (20% O2) often used to culture 
cells.(160,161) 
 
4.5 Implications and clinical relevance 
Results from this study has provided evidence that combination therapy may provide 
synergistic effects suggesting that identification of the effective combination of stem cell 
which exert synergistic and complimentary effects on cardiac repair could be more beneficial. 
Although combination of stem cells is appealing, the technical difficulties and invasiveness of 
64 
procuring different stem cell population needs to be assessed and compared against the 
therapeutic benefits of combination therapy. 
Preconditioning refers to treatment of stem cells to enhance or modulate their therapeutic 
actions. Hypoxia increased angiogenic effects of CM from CPCs, thereby suggesting that 
hypoxic pre-conditioning may be another approach to effectively improve the therapeutic 
effects of stem cells. 
 
4.6 Future directions 
The exact mechanisms for the different functional effects of RAA CPCs and LV CPCs are not 
clear and warrants further investigation. Paracrine factors released by CPCs are not only 
limited to cytokines but include exosomes and microRNAs. Assessment of the paracrine 
profile could deduce mechanisms involved in the paracrine effects of CPCs. 
While the in vitro results may be promising, in vivo studies are needed to confirm the 
therapeutic effects of RAA CPCs and LV CPCs, as well as their use in combination. Other 
paracrine mediated effects such as immunomodulation and stimulation of endogenous 
stem/progenitor cells can be investigated in vivo. 
Combination of RAA CPCs and LV CPCs increased cardioprotection by reducing apoptosis 
and increasing HIF-1α expression in cardiomyocytes through paracrine factors. A previous 
study showed CM from RAA CPCs had the highest cardioprotective effects compared to LV 
CPCs and EPCs through activation of cell proliferation and reduced apoptotic cell death.(8) 
Therefore, other cardioprotective effects such as cell proliferation should be investigated to 
give a better indication of the cardioprotective effects of combination of RAA CPCs and LV 
CPCs.  
The paracrine effects of CPCs on proliferation and migration of endothelial cells were not 
investigated in this study, which are essential processes for angiogenesis. It was previously 
shown that CM from RAA CPCs and LV CPCs had superior migration potential on 
endothelial cells compared to CM from EPCs.(8) Also, other ASC populations can increase 
proliferation and migration of endothelial cells by releasing pro-angiogenic factors.(7,106) 
Therefore, it would be interesting to measure the potential of CM on proliferation and 
migration of endothelial cells using a combination of RAA CPCs and LV CPCs, and to 
compare cells used in this study to other ASC populations. 
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The procurement of heart tissue for isolation of CPCs is an invasive procedure, especially for 
the left ventricle which is not routinely obtained in CABG surgery. It would be interesting to 
investigate if procurement of heart tissue from less invasive procedures, such as 
endomyocardial biopsies, have the same functional effects as the CPCs in this study. This 
would provide a more clinically viable method to obtain CPCs, as well as the possibility to 
isolate CPCs prior to ischaemic injury to the heart in high-risk individuals. 
CPCs used in this study are heterogeneous, which may be similar in composition to CDCs 
another heterogeneous population of CPCs. Other CPCs in the current literature are often 
isolated and characterised based on specific cell markers or techniques. Therefore, further 
characterisation may reveal distinct differences in the composition or population of stem cells 




This study provides evidence that different combination of stem cells has synergistic or 
complimentary paracrine effects thereby enhancing the therapeutic potential of stem cells. 
Combination of RAA CPCs and LV CPCs synergistically improved VEGF-A secretion, 
stimulated HIF-1α expression in cardiomyocytes in hypoxia and increased angiogenesis in 
endothelial cells by paracrine mechanisms. Stated as part of the ‘next-generation’ of cell 
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Table A1 List of solutions and their composition. 
Solution Composition 
Phosphate buffered saline (PBS) 137 mM Sodium chloride 
10 mM Sodium monobasic 
1.4 mM Potassium phosphate dibasic 
2.7 mM Potassium chloride 
Hank’s balanced salt solution 
(HBSS) 
5.4 mM Potassium chloride 
0.3 mM Sodium phosphate hepta hydrate 
0.4 mM Potassium monobasic 
4.2 mM Sodium bicarbonate 
1.3 mM Calcium chloride 
0.5 mM Magnesium chloride hexa hydrate 
0.6 mM Magnesium sulphate hepta hydrate 
137 mM Sodium chloride 
5.6 mM D-glucose 
pH adjusted to 7.4 
Krebs Ringer Henseleit (KRH) 
buffer 
116 mM Sodium chloride 
4 mM Potassium chloride 
1 mM Magnesium chloride 
1.8 mM Calcium chloride 
25 mM Glucose 
10 mM HEPES 
pH adjusted to 7.4 
Tris-EDTA (TE) buffer 100 mM Tris∙hydrochloride 
1 mM EDTA, pH 8.0 
Flow cytometry buffer HBSS supplemented with 
• 3% FBS 
• 10 mM HEPES 




Table A2 List of media used for cell culture experiments. 
Media Composition 
Ham’s F12 complete media Ham’s F12 nutrient mix supplemented with 
• 10% FBS 
• 1X antibiotic-antimycotic (anti-anti) 
• 10 ng/mL human FGF2 
• 0.005 U/mL human EPO 
Serum-free Ham’s F12 media Ham’s F12 nutrient mix supplemented with 1X anti-
anti 
DMEM/F12 complete media DMEM/F12 media supplemented with 
• 12.5% FBS 
• 1X anti-anti 
AC16 cardiomyocyte freezing 
media 
DMEM/F12 complete media supplemented with 10% 
DMSO 
EGM-2 complete media EBM-2 supplemented with EGM-2 SingleQuots 
containing 
• Human EGF 
• Vascular endothelial growth factor 
•  R3-IGF-1 
• Ascorbic acid 
• Hydrocortisone 




Serum-free EBM-2 media EBM-2 supplemented with 1X anti-anti 
HUVEC freezing media EGM-2 complete media supplemented with 
• 10% FBS 




Table A3 List of antibodies used. 
















Primary conjugated Mouse Human eBioscience, USA 
(25-1057-42) 
 
Table A4 List of primers used for PCR. 
Gene Primer Sequence (5’ to 3’) Species 
specificity 
Manufacturer  
HIF1A Forward: AAAATCTCATCCAAGAAGCC 
Reverse: AATGTTCCAATTCCTACTGC 
Human Sigma-Aldrich,  
USA 
AKT1 Forward: AAGTACTCTTTCCAGACCC 
Reverse: TTCTCCAGCTTGAGGTC 
Human Sigma-Aldrich,  
USA 
FGF2 Forward: TGGCTTCTAAATGTGTTACG 
Reverse: GTTTATACTGCCCAGTTCG 
Human Sigma-Aldrich,  
USA 
PDGFA Forward: TAGGGAGTGAGGATTCTTTG 
Reverse: CGAGGAATCTCGTAAATGAC 





Table A5 List of kits used. 
Kit Manufacturer  
(Cat no.) 
AbC anti-mouse bead kit Invitrogen, USA 
(A10344) 
Caspase 3/7 Glo assay Promega, UK 
(G8093) 




Human IGF-1 ELISA kit ELISAkit.com, Australia 
(0028) 
Human VEGF-A ELISA kit ELISAkit.com, Australia 
(0035) 
PrimeScript RT reagent kit Takara, Japan 
(RR037A) 
SYBR Premix Ex Taq Takara, Japan 
(RR420L) 
HIF1a Human SimpleStep 
ELISA kit  
Abcam, UK 
(ab171577) 
 
